Companies: 10,652     total market cap: $139.387 T
โ‚ฌEUR๐Ÿ‡ช๐Ÿ‡บโ‚นINR๐Ÿ‡ฎ๐Ÿ‡ณยฃGBP๐Ÿ‡ฌ๐Ÿ‡ง$CAD๐Ÿ‡จ๐Ÿ‡ฆ$AUD๐Ÿ‡ฆ๐Ÿ‡บ$NZD๐Ÿ‡ณ๐Ÿ‡ฟ$HKD๐Ÿ‡ญ๐Ÿ‡ฐ$SGD๐Ÿ‡ธ๐Ÿ‡ฌ
IDEX
IEX
#1461
Rank
$14.94 B
Marketcap
๐Ÿ‡บ๐Ÿ‡ธ United States
Country
$198.55
Share price
-0.59%
Change (1 day)
-8.59%
Change (1 year)
IDEX Corporation, is an American company founded in 1988 that develops, designs and manufactures fluidic systems and specialty technical handling.
  1. IDEX
  2. Quarterly Reports (10-Q)
  3. Financial Year FY2023 Q3

IDEX - 10-Q quarterly report FY2023 Q3


Text size:
false2023Q3000083210112/31http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent00008321012023-01-012023-09-3000008321012023-10-20xbrli:shares00008321012023-07-012023-09-30iso4217:USD00008321012022-07-012022-09-3000008321012022-01-012022-09-30iso4217:USDxbrli:shares00008321012023-09-3000008321012022-12-310000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-06-300000832101us-gaap:RetainedEarningsMember2023-06-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000832101us-gaap:TreasuryStockCommonMember2023-06-300000832101us-gaap:ParentMember2023-06-300000832101us-gaap:NoncontrollingInterestMember2023-06-3000008321012023-06-300000832101us-gaap:RetainedEarningsMember2023-07-012023-09-300000832101us-gaap:ParentMember2023-07-012023-09-300000832101us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300000832101us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-07-012023-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-09-300000832101us-gaap:RetainedEarningsMember2023-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000832101us-gaap:TreasuryStockCommonMember2023-09-300000832101us-gaap:ParentMember2023-09-300000832101us-gaap:NoncontrollingInterestMember2023-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-06-300000832101us-gaap:RetainedEarningsMember2022-06-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000832101us-gaap:TreasuryStockCommonMember2022-06-300000832101us-gaap:ParentMember2022-06-300000832101us-gaap:NoncontrollingInterestMember2022-06-3000008321012022-06-300000832101us-gaap:RetainedEarningsMember2022-07-012022-09-300000832101us-gaap:ParentMember2022-07-012022-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000832101us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-07-012022-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-09-300000832101us-gaap:RetainedEarningsMember2022-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000832101us-gaap:TreasuryStockCommonMember2022-09-300000832101us-gaap:ParentMember2022-09-300000832101us-gaap:NoncontrollingInterestMember2022-09-3000008321012022-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310000832101us-gaap:RetainedEarningsMember2022-12-310000832101us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000832101us-gaap:TreasuryStockCommonMember2022-12-310000832101us-gaap:ParentMember2022-12-310000832101us-gaap:NoncontrollingInterestMember2022-12-310000832101us-gaap:RetainedEarningsMember2023-01-012023-09-300000832101us-gaap:ParentMember2023-01-012023-09-300000832101us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000832101us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310000832101us-gaap:RetainedEarningsMember2021-12-310000832101us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000832101us-gaap:TreasuryStockCommonMember2021-12-310000832101us-gaap:ParentMember2021-12-310000832101us-gaap:NoncontrollingInterestMember2021-12-3100008321012021-12-310000832101us-gaap:RetainedEarningsMember2022-01-012022-09-300000832101us-gaap:ParentMember2022-01-012022-09-300000832101us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000832101us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000832101us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000832101us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-012022-09-300000832101iex:FivePointOneThreePercentSeniorNotesMemberus-gaap:SeniorNotesMember2023-09-30xbrli:pure0000832101us-gaap:SeniorNotesMemberiex:ThreePointTwoPercentSeniorNotesMember2023-09-300000832101iex:IridianSpectralTechnologiesMember2023-05-192023-05-190000832101iex:IridianSpectralTechnologiesMember2023-05-190000832101iex:IridianSpectralTechnologiesMemberus-gaap:TradeNamesMember2023-05-192023-05-190000832101iex:IridianSpectralTechnologiesMemberus-gaap:CustomerRelationshipsMember2023-05-192023-05-190000832101iex:IridianSpectralTechnologiesMemberus-gaap:UnpatentedTechnologyMember2023-05-192023-05-190000832101iex:NexsightLLCMember2022-02-280000832101iex:NexsightLLCMemberus-gaap:TradeNamesMember2022-02-282022-02-280000832101iex:NexsightLLCMemberus-gaap:CustomerRelationshipsMember2022-02-282022-02-280000832101iex:NexsightLLCMemberus-gaap:SoftwareDevelopmentMember2022-02-282022-02-280000832101iex:NexsightLLCMember2022-02-282022-02-280000832101iex:KZValveMember2022-05-022022-05-020000832101iex:KZValveMember2022-05-020000832101us-gaap:TradeNamesMemberiex:KZValveMember2022-05-022022-05-020000832101us-gaap:CustomerRelationshipsMemberiex:KZValveMember2022-05-022022-05-020000832101iex:KZValveMemberus-gaap:UnpatentedTechnologyMember2022-05-022022-05-020000832101iex:MuonLLCMember2022-11-182022-11-180000832101iex:MuonLLCMemberiex:CashOnHandMember2022-11-182022-11-180000832101us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberiex:MuonLLCMember2022-11-182022-11-180000832101us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberiex:MuonLLCMember2022-11-182022-11-180000832101iex:MuonLLCMember2022-11-180000832101iex:MuonLLCMemberus-gaap:TradeNamesMember2022-11-182022-11-180000832101iex:MuonLLCMemberus-gaap:CustomerRelationshipsMember2022-11-182022-11-180000832101iex:MuonLLCMemberus-gaap:UnpatentedTechnologyMember2022-11-182022-11-180000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:IridianSpectralTechnologiesMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:IridianSpectralTechnologiesMember2023-01-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:MuonLLCMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:MuonLLCMember2022-01-012022-09-300000832101iex:IridianSpectralTechnologiesMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000832101iex:IridianSpectralTechnologiesMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000832101iex:NexsightLLCMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101iex:KZValveMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101iex:MicropumpMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-08-032023-08-030000832101iex:KnightLLCMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-09-092022-09-090000832101iex:ConvertiblePromissoryNoteMember2022-01-012022-12-310000832101iex:ConvertiblePromissoryNoteMember2021-01-012021-12-310000832101iex:ConvertiblePromissoryNoteMember2023-01-012023-09-30iex:segment0000832101iex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101iex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101iex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101iex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101iex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101iex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101iex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101iex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101iex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101iex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101iex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101iex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101us-gaap:IntersegmentEliminationMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000832101us-gaap:IntersegmentEliminationMember2022-07-012022-09-300000832101us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000832101us-gaap:IntersegmentEliminationMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMember2022-01-012022-09-300000832101us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000832101us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000832101us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000832101us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-12-310000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-12-310000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-12-310000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-12-310000832101us-gaap:CorporateNonSegmentMember2023-09-300000832101us-gaap:CorporateNonSegmentMember2022-12-310000832101iex:PumpsMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101iex:PumpsMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101iex:PumpsMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101iex:PumpsMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:Water1Member2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:Water1Member2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:Water1Member2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:Water1Member2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:EnergyMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:EnergyMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:EnergyMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:EnergyMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:AgricultureMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:AgricultureMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:AgricultureMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:AgricultureMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101iex:ValvesMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101iex:ValvesMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101iex:ValvesMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101iex:ValvesMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101iex:ScientificFluidicsandOpticsMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101iex:ScientificFluidicsandOpticsMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101iex:ScientificFluidicsandOpticsMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101iex:ScientificFluidicsandOpticsMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMemberiex:PerformancePneumaticTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMemberiex:PerformancePneumaticTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMemberiex:PerformancePneumaticTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMemberiex:PerformancePneumaticTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:SealingSolutionsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:SealingSolutionsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:SealingSolutionsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:SealingSolutionsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101iex:MaterialProcessingTechnologiesMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101iex:MaterialProcessingTechnologiesMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101iex:MaterialProcessingTechnologiesMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101iex:MaterialProcessingTechnologiesMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101iex:MicropumpMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101iex:MicropumpMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101iex:MicropumpMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101iex:MicropumpMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101iex:FireandSafetyMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101iex:FireandSafetyMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101iex:FireandSafetyMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101iex:FireandSafetyMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:DispensingMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:DispensingMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:DispensingMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:DispensingMember2022-01-012022-09-300000832101iex:BandItMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101iex:BandItMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101iex:BandItMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101iex:BandItMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101country:USus-gaap:OperatingSegmentsMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:NorthAmericaExcludingUnitedStatesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:NorthAmericaExcludingUnitedStatesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMember2023-07-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMembersrt:AsiaMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMembersrt:AsiaMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMember2023-07-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101country:USus-gaap:OperatingSegmentsMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:NorthAmericaExcludingUnitedStatesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:NorthAmericaExcludingUnitedStatesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMember2022-07-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMembersrt:AsiaMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMembersrt:AsiaMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMember2022-07-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101country:USus-gaap:OperatingSegmentsMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:NorthAmericaExcludingUnitedStatesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:NorthAmericaExcludingUnitedStatesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMember2023-01-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMembersrt:AsiaMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMembersrt:AsiaMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMember2023-01-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101country:USus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101country:USus-gaap:OperatingSegmentsMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberiex:NorthAmericaExcludingUnitedStatesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberiex:NorthAmericaExcludingUnitedStatesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:NorthAmericaExcludingUnitedStatesMember2022-01-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101srt:EuropeMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMembersrt:AsiaMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMembersrt:AsiaMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMembersrt:AsiaMember2022-01-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101iex:OtherGeographicalAreasMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000832101us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000832101us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012022-09-300000832101us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300000832101us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-09-300000832101us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000832101us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012022-09-300000832101us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300000832101us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-09-300000832101iex:BilledReceivablesMember2023-09-300000832101iex:BilledReceivablesMember2022-12-310000832101iex:FluidAndMeteringTechnologiesMember2022-12-310000832101iex:HealthAndScienceTechnologiesMember2022-12-310000832101iex:FireAndSafetyDiversifiedProductsMember2022-12-310000832101iex:FluidAndMeteringTechnologiesMember2023-09-300000832101iex:HealthAndScienceTechnologiesMember2023-09-300000832101iex:FireAndSafetyDiversifiedProductsMember2023-09-300000832101us-gaap:PatentsMember2023-09-300000832101us-gaap:PatentsMember2022-12-310000832101us-gaap:TradeNamesMember2023-09-300000832101us-gaap:TradeNamesMember2022-12-310000832101us-gaap:CustomerRelationshipsMember2023-09-300000832101us-gaap:CustomerRelationshipsMember2022-12-310000832101us-gaap:UnpatentedTechnologyMember2023-09-300000832101us-gaap:UnpatentedTechnologyMember2022-12-310000832101us-gaap:SoftwareDevelopmentMember2023-09-300000832101us-gaap:SoftwareDevelopmentMember2022-12-310000832101iex:BanjoTradeNameMember2023-09-300000832101iex:BanjoTradeNameMember2022-12-310000832101iex:AkronBrasstradenameMember2023-09-300000832101iex:AkronBrasstradenameMember2022-12-310000832101us-gaap:SeniorNotesMemberiex:ThreePointTwoPercentSeniorNotesMember2022-12-310000832101iex:ThreePointThreeSevenPercentSeniorNotesMemberus-gaap:SeniorNotesMember2023-09-300000832101iex:ThreePointThreeSevenPercentSeniorNotesMemberus-gaap:SeniorNotesMember2022-12-310000832101iex:FivePointOneThreePercentSeniorNotesMemberus-gaap:SeniorNotesMember2022-12-310000832101iex:ThreePointZeroPercentSeniorNotesDueMay2030Memberus-gaap:SeniorNotesMember2023-09-300000832101iex:ThreePointZeroPercentSeniorNotesDueMay2030Memberus-gaap:SeniorNotesMember2022-12-310000832101us-gaap:SeniorNotesMemberiex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member2023-09-300000832101us-gaap:SeniorNotesMemberiex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member2022-12-310000832101us-gaap:RevolvingCreditFacilityMember2023-09-300000832101us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-09-300000832101us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-12-310000832101us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-09-300000832101us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-12-310000832101us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-07-012023-09-300000832101us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-06-300000832101iex:FivePointOneThreePercentSeniorNotesMemberus-gaap:SeniorNotesMember2023-06-130000832101us-gaap:SeniorNotesMemberiex:ThreePointTwoPercentSeniorNotesMember2023-06-130000832101srt:MinimumMemberiex:FivePointOneThreePercentSeniorNotesMemberus-gaap:SeniorNotesMember2023-06-130000832101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2023-09-300000832101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2022-12-310000832101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000832101us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000832101us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000832101us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300000832101us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000832101us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-31iex:option0000832101us-gaap:BuildingMember2023-09-300000832101us-gaap:BuildingMember2022-12-310000832101us-gaap:EquipmentMember2023-09-300000832101us-gaap:EquipmentMember2022-12-310000832101iex:BuildingAndEquipmentMember2023-09-300000832101iex:BuildingAndEquipmentMember2022-12-310000832101us-gaap:VehiclesMember2023-09-300000832101us-gaap:VehiclesMember2022-12-310000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-07-012023-09-300000832101us-gaap:CorporateNonSegmentMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000832101us-gaap:EmployeeSeveranceMember2023-07-012023-09-300000832101us-gaap:FacilityClosingMember2023-07-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2023-01-012023-09-300000832101us-gaap:CorporateNonSegmentMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000832101us-gaap:FacilityClosingMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000832101us-gaap:EmployeeSeveranceMember2023-01-012023-09-300000832101us-gaap:FacilityClosingMember2023-01-012023-09-300000832101us-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2020-04-012020-06-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberus-gaap:EmployeeSeveranceMember2022-07-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberus-gaap:EmployeeSeveranceMember2022-07-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-07-012022-09-300000832101us-gaap:CorporateNonSegmentMemberus-gaap:EmployeeSeveranceMember2022-07-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000832101us-gaap:EmployeeSeveranceMember2022-07-012022-09-300000832101us-gaap:FacilityClosingMember2022-07-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FluidAndMeteringTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:HealthAndScienceTechnologiesMember2022-01-012022-09-300000832101us-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:OperatingSegmentsMemberiex:FireAndSafetyDiversifiedProductsMember2022-01-012022-09-300000832101us-gaap:CorporateNonSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300000832101us-gaap:FacilityClosingMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000832101us-gaap:EmployeeSeveranceMember2022-01-012022-09-300000832101us-gaap:FacilityClosingMember2022-01-012022-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000832101us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000832101us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300000832101us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000832101us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000832101us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-3000008321012020-03-172020-03-1700008321012015-12-012015-12-0100008321012022-10-012022-10-310000832101iex:EmployeesMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300000832101us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000832101us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000832101us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000832101us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000832101us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000832101us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000832101us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000832101us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMemberiex:AcceleratedStockRetireeEligibilityMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeStockOptionMemberiex:AcceleratedStockRetireeEligibilityMember2023-01-012023-09-300000832101us-gaap:EmployeeStockOptionMember2022-12-310000832101us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000832101us-gaap:EmployeeStockOptionMember2023-09-300000832101us-gaap:RestrictedStockMemberiex:EmployeesandNonemployeeDirectorsMember2023-01-012023-09-300000832101us-gaap:RestrictedStockMember2022-12-310000832101us-gaap:RestrictedStockMember2023-01-012023-09-300000832101us-gaap:RestrictedStockMember2023-09-300000832101us-gaap:RestrictedStockMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000832101us-gaap:RestrictedStockMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000832101us-gaap:RestrictedStockMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000832101us-gaap:RestrictedStockMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMember2023-01-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMember2022-01-012022-09-300000832101us-gaap:RestrictedStockMember2023-07-012023-09-300000832101us-gaap:RestrictedStockMember2022-07-012022-09-300000832101us-gaap:RestrictedStockMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMemberiex:AcceleratedStockRetireeEligibilityMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RestrictedStockMemberiex:AcceleratedStockRetireeEligibilityMember2023-01-012023-09-300000832101iex:CashsettledRestrictedStockMember2023-01-012023-09-300000832101iex:CashsettledRestrictedStockMember2022-12-310000832101iex:CashsettledRestrictedStockMember2023-09-300000832101iex:CashsettledRestrictedStockMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000832101iex:CashsettledRestrictedStockMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000832101iex:CashsettledRestrictedStockMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000832101iex:CashsettledRestrictedStockMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:CashsettledRestrictedStockMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:CashsettledRestrictedStockMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:CashsettledRestrictedStockMember2023-01-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:CashsettledRestrictedStockMember2022-01-012022-09-300000832101iex:CashsettledRestrictedStockMember2023-07-012023-09-300000832101iex:CashsettledRestrictedStockMember2022-07-012022-09-300000832101iex:CashsettledRestrictedStockMember2022-01-012022-09-300000832101us-gaap:PerformanceSharesMember2023-01-012023-09-300000832101us-gaap:PerformanceSharesMember2022-01-012022-09-300000832101us-gaap:PerformanceSharesMember2022-12-310000832101us-gaap:PerformanceSharesMember2023-09-300000832101us-gaap:PerformanceSharesMember2023-01-312023-01-310000832101us-gaap:PerformanceSharesMember2023-02-012023-02-280000832101us-gaap:PerformanceSharesMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000832101us-gaap:PerformanceSharesMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000832101us-gaap:PerformanceSharesMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000832101us-gaap:PerformanceSharesMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:PerformanceSharesMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:PerformanceSharesMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:PerformanceSharesMember2023-01-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300000832101us-gaap:PerformanceSharesMember2023-07-012023-09-300000832101us-gaap:PerformanceSharesMember2022-07-012022-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:AcceleratedStockRetireeEligibilityMemberus-gaap:PerformanceSharesMember2023-07-012023-09-300000832101us-gaap:SellingGeneralAndAdministrativeExpensesMemberiex:AcceleratedStockRetireeEligibilityMemberus-gaap:PerformanceSharesMember2023-01-012023-09-300000832101country:USus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000832101us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000832101country:USus-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000832101us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000832101country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000832101us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000832101country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000832101us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000832101us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000832101us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000832101us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000832101us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000832101us-gaap:PensionPlansDefinedBenefitMember2023-09-300000832101us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________ 
Form 10-Q
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedSeptember 30, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period fromto
Commission File Number: 1-10235
IDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware36-3555336
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
3100 Sanders Road,Suite 301,Northbrook,Illinois60062
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (847) 498-7070
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $.01 per shareIEXNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  ☑    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes  ☑    No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑
Accelerated filer  ☐
Non-accelerated filer ☐
Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes  ☐   No  ☑     
Number of shares of common stock of IDEX Corporation outstanding as of October 20, 2023: 75,625,539.
        

TABLE OF CONTENTS
 
Item 1.
1
1
2
3
4
5
6
6
6
11
11
13
16
17
17
19
20
21
22
25
25
25
29
30
30
Item 2.
31
Item 3.
48
Item 4.
48
Item 1.
49
Item 1A.
49
Item 2.
49
Item 5.
49
Item 6.
50
51

PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
(unaudited)

 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Net sales$793.4 $824.0 $2,485.0 $2,371.2 
Cost of sales443.8 442.2 1,374.9 1,290.0 
Gross profit349.6 381.8 1,110.1 1,081.2 
Selling, general and administrative expenses165.9 161.9 529.9 483.7 
Restructuring expenses and asset impairments4.1 17.7 8.2 21.1 
Operating income179.6 202.2 572.0 576.4 
Gain on sale of business(93.8)(34.8)(93.8)(34.8)
Other (income) expense - net(2.1)(1.0)5.6 (3.3)
Interest expense13.7 9.6 40.1 28.6 
Income before income taxes261.8 228.4 620.1 585.9 
Provision for income taxes52.8 49.7 132.8 129.2 
Net income209.0 178.7 487.3 456.7 
Net loss attributable to noncontrolling interest0.1 — 0.2 0.2 
Net income attributable to IDEX$209.1 $178.7 $487.5 $456.9 
Earnings per common share:
Basic earnings per common share attributable to IDEX$2.76 $2.37 $6.44 $6.02 
Diluted earnings per common share attributable to IDEX$2.75 $2.36 $6.42 $6.00 
Share data:
Basic weighted average common shares outstanding75.6 75.4 75.6 75.8 
Diluted weighted average common shares outstanding75.9 75.8 75.9 76.1 
    
See Notes to Condensed Consolidated Financial Statements
1
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(unaudited)
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Net income$209.0 $178.7 $487.3 $456.7 
Other comprehensive loss:
Pension and other postretirement adjustments, net of tax(0.3)0.6 (0.8)1.8 
Cumulative translation adjustment(58.1)(94.9)(19.2)(196.3)
Other comprehensive loss(58.4)(94.3)(20.0)(194.5)
Comprehensive income150.6 84.4 467.3 262.2 
Comprehensive loss attributable to noncontrolling interest0.1 — 0.2 0.2 
Comprehensive income attributable to IDEX$150.7 $84.4 $467.5 $262.4 
See Notes to Condensed Consolidated Financial Statements
2
IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)
(unaudited)
 
September 30, 2023December 31, 2022
ASSETS
Current assets
Cash and cash equivalents$562.7 $430.2 
Receivables - net of allowance for credit losses of $6.9 and $8.0, respectively
430.6 442.8 
Inventories - net446.6 470.9 
Other current assets78.3 55.4 
Total current assets1,518.2 1,399.3 
Property, plant and equipment - net of accumulated depreciation of $539.6 and $516.7, respectively
421.5 382.1 
Goodwill2,677.3 2,638.1 
Intangible assets - net919.6 947.8 
Other noncurrent assets133.0 144.6 
Total assets$5,669.6 $5,511.9 
LIABILITIES AND EQUITY
Current liabilities
Trade accounts payable$176.3 $208.9 
Accrued expenses262.0 289.1 
Current portion of long-term borrowings - net0.7 — 
Dividends payable48.5 45.6 
Total current liabilities487.5 543.6 
Long-term borrowings - net1,320.8 1,468.7 
Deferred income taxes279.3 264.2 
Other noncurrent liabilities194.8 195.8 
Total liabilities2,282.4 2,472.3 
Commitments and contingencies (Note 17)
Shareholders’ equity
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None
— — 
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value
Issued: 89,962,648 shares at September 30, 2023 and 90,064,988 shares at December 31, 2022
0.9 0.9 
Additional paid-in capital836.1 817.2 
Retained earnings3,874.0 3,531.7 
Treasury stock at cost: 14,337,849 shares at September 30, 2023 and 14,451,032 shares at December 31, 2022
(1,177.7)(1,184.3)
Accumulated other comprehensive loss(146.2)(126.2)
Total shareholders’ equity3,387.1 3,039.3 
Noncontrolling interest0.1 0.3 
Total equity3,387.2 3,039.6 
Total liabilities and equity$5,669.6 $5,511.9 
See Notes to Condensed Consolidated Financial Statements
3
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Dollars in millions)
(unaudited)

Accumulated Other Comprehensive Loss
 Common
Stock and
Additional
Paid-In Capital		Retained
Earnings		Cumulative Translation AdjustmentRetirement Benefits AdjustmentTreasury
Stock		Total
Shareholders’
Equity		Noncontrolling InterestTotal Equity
Balance, June 30, 2023$835.1 $3,713.4 $(98.2)$10.4 $(1,182.0)$3,278.7 $0.2 $3,278.9 
Net income (loss)— 209.1 — — — 209.1 (0.1)209.0 
Cumulative translation adjustment— — (58.1)— — (58.1)— (58.1)
Net change in retirement obligations (net of tax of $—)
— — — (0.3)— (0.3)— (0.3)
Net issuance of 29,360 shares of common stock (net of tax of $0.4)
— — — — 4.3 4.3 — 4.3 
Share-based compensation1.9 — — — — 1.9 — 1.9 
Cash dividends declared - $0.64 per common share outstanding
— (48.5)— — — (48.5)— (48.5)
Balance, September 30, 2023$837.0 $3,874.0 $(156.3)$10.1 $(1,177.7)3,387.1 $0.1 $3,387.2 
Accumulated Other Comprehensive Loss
 Common
Stock and
Additional
Paid-In Capital		Retained
Earnings		Cumulative Translation AdjustmentRetirement Benefits AdjustmentTreasury
Stock		Total
Shareholders’
Equity		Noncontrolling InterestTotal Equity
Balance, June 30, 2022$810.0 $3,313.8 $(163.6)$(6.2)$(1,165.8)$2,788.2 $(0.2)$2,788.0 
Net income— 178.7 — — — 178.7 — 178.7 
Cumulative translation adjustment— — (94.9)— — (94.9)— (94.9)
Net change in retirement obligations (net of tax of $—)
— — — 0.6 — 0.6 — 0.6 
Net issuance of 28,034 shares of common stock (net of tax of $0.4)
— — — — 3.6 3.6 — 3.6 
Repurchase of 166,433 shares of common stock
— — — — (30.9)(30.9)— (30.9)
Share-based compensation2.9 — — — — 2.9 — 2.9 
Cash dividends declared - $0.60 per common share outstanding
— (45.4)— — — (45.4)— (45.4)
Balance, September 30, 2022$812.9 $3,447.1 $(258.5)$(5.6)$(1,193.1)$2,802.8 $(0.2)$2,802.6 
Accumulated Other Comprehensive Loss
 Common
Stock and
Additional
Paid-In Capital		Retained
Earnings		Cumulative Translation AdjustmentRetirement Benefits AdjustmentTreasury
Stock		Total
Shareholders’
Equity		Noncontrolling InterestTotal Equity
Balance, December 31, 2022$818.1 $3,531.7 $(137.1)$10.9 $(1,184.3)$3,039.3 $0.3 $3,039.6 
Net income (loss)— 487.5 — — — 487.5 (0.2)487.3 
Cumulative translation adjustment— — (19.2)— — (19.2)— (19.2)
Net change in retirement obligations (net of tax of $(0.2))
— — — (0.8)— (0.8)— (0.8)
Net issuance of 120,767 shares of common stock (net of tax of $2.5)
— — — — 7.7 7.7 — 7.7 
Repurchase of 5,400 shares of common stock
— — — — (1.1)(1.1)— (1.1)
Share-based compensation18.9 — — — — 18.9 — 18.9 
Cash dividends declared - $1.92 per common share outstanding
— (145.2)— — — (145.2)— (145.2)
Balance, September 30, 2023$837.0 $3,874.0 $(156.3)$10.1 $(1,177.7)3,387.1 $0.1 $3,387.2 
Accumulated Other Comprehensive Loss
 Common
Stock and
Additional
Paid-In Capital		Retained
Earnings		Cumulative Translation AdjustmentRetirement Benefits AdjustmentTreasury
Stock		Total
Shareholders’
Equity		Noncontrolling InterestTotal Equity
Balance, December 31, 2021$796.5 $3,126.5 $(62.2)$(7.4)$(1,050.3)$2,803.1 $— $2,803.1 
Net income (loss)— 456.9 — — — 456.9 (0.2)456.7 
Cumulative translation adjustment— — (196.3)— — (196.3)— (196.3)
Net change in retirement obligations (net of tax of $0.7)
— — — 1.8 — 1.8 — 1.8 
Net issuance of 117,656 shares of common stock (net of tax of $2.5)
— — — — 3.9 3.9 — 3.9 
Repurchase of 788,623 shares of common stock
— — — — (146.7)(146.7)— (146.7)
Share-based compensation16.4 — — — — 16.4 — 16.4 
Cash dividends declared - $1.80 per common share outstanding
— (136.3)— — — (136.3)— (136.3)
Balance, September 30, 2022$812.9 $3,447.1 $(258.5)$(5.6)$(1,193.1)$2,802.8 $(0.2)$2,802.6 
See Notes to Condensed Consolidated Financial Statements
4
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(unaudited)
 Nine Months Ended September 30,
 20232022
Cash flows from operating activities
Net income$487.3 $456.7 
Adjustments to reconcile net income to net cash flows provided by operating activities:
Gain on sale of business(93.8)(34.8)
Asset impairments0.8 17.0 
Credit loss on note receivable from collaborative partner7.7 — 
Depreciation41.9 37.0 
Amortization of intangible assets70.6 49.2 
Share-based compensation expense18.9 16.4 
Deferred income taxes(1.8)0.2 
Changes in (net of the effect from acquisitions/divestitures and foreign currency translation):
Receivables11.6 (62.5)
Inventories24.5 (99.6)
Other current assets0.3 (4.8)
Trade accounts payable(30.2)25.6 
Deferred revenue5.6 (24.7)
Accrued expenses(34.0)13.1 
Other - net6.3 1.3 
Net cash flows provided by operating activities515.7 390.1 
Cash flows from investing activities
Capital expenditures(68.3)(48.0)
Acquisition of businesses, net of cash acquired(110.3)(232.6)
Proceeds from sale of business, net of cash remitted110.3 49.4 
Purchases of marketable securities(24.6)— 
Other - net2.9 6.8 
Net cash flows used in investing activities(90.0)(224.4)
Cash flows from financing activities
Borrowings under revolving credit facilities— 40.0 
Payments under revolving credit facilities— (40.0)
Proceeds from issuance of 5.13% Senior Notes
100.0 — 
Payment of 3.20% Senior Notes
(100.0)— 
Payments under Term Facility(150.0)— 
Cash dividends paid to shareholders(142.3)(132.2)
Net proceeds from stock option exercises7.7 3.9 
Repurchases of common stock(1.1)(146.3)
Other - net(1.0)— 
Net cash flows used in financing activities(286.7)(274.6)
Effect of exchange rate changes on cash and cash equivalents(6.5)(65.8)
Net increase (decrease) in cash and cash equivalents132.5 (174.7)
Cash and cash equivalents at beginning of year430.2 855.4 
Cash and cash equivalents at end of period$562.7 $680.7 
Supplemental cash flow information
Cash paid for:
Interest$30.5 $18.9 
Income taxes147.1 129.5 

See Notes to Condensed Consolidated Financial Statements
5

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

1.    Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the entire year.

The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Recently Adopted Accounting Standards

The Financial Accounting Standards Board establishes changes to U.S. GAAP in the form of accounting standards updates (“ASUs”) to the Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASUs. Any recent ASUs were assessed and determined to be either not applicable or are expected to have an immaterial impact on the Company’s Condensed Consolidated Financial Statements.

2.    Acquisitions and Divestitures

All of the Company’s acquisitions of businesses have been accounted for under ASC 805, Business Combinations. Accordingly, the assets and liabilities of the acquired companies, after adjustments to reflect the fair values assigned to the assets and liabilities, have been included in the Company’s Condensed Consolidated Balance Sheets from their respective dates of acquisition. The results of operations of Nexsight, LLC and its businesses Envirosight, WinCan, MyTana and Pipeline Renewal Technologies (“Nexsight”) (acquired February 28, 2022), KZ CO. (“KZValve”) (acquired May 2, 2022), Muon B.V. and its subsidiaries (“Muon Group”) (acquired November 18, 2022) and Iridian Spectral Technologies ("Iridian") (acquired May 19, 2023) have been included in the Company’s Condensed Consolidated Statements of Income since the respective dates of acquisition. The results of operations of Micropump, Inc. (“Micropump”) (sold on August 3, 2023) and Knight LLC (“Knight”) (sold on September 9, 2022) have been included in the Company’s Condensed Consolidated Statements of Income through the respective dates of disposition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on the Company’s Condensed Consolidated Financial Statements individually or in the aggregate. In addition, the divestitures did not represent a strategic shift that had a major effect on operations and financial results and, therefore, did not qualify for presentation as discontinued operations.

2023 Acquisitions

Iridian

On May 19, 2023, the Company acquired Iridian in a stock acquisition. Iridian is a global leader in designing and manufacturing thin-film, multi-layer optical filters serving the laser communications, telecommunications and life sciences markets and expands the Company’s array of optical technology offerings. Headquartered in Ottawa, Ontario, Canada, Iridian operates in the Company’s Scientific Fluidics & Optics reporting unit within the Health & Science Technologies (“HST”) segment. Iridian was acquired for cash consideration of $110.3 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $53.6 million and $45.6 million, respectively. The goodwill is not deductible for tax purposes.

6

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The Company made a preliminary allocation of the purchase price for the Iridian acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.

The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
Total
Current assets, net of cash acquired$10.6 
Property, plant and equipment19.9 
Goodwill53.6 
Intangible assets45.6 
Other noncurrent assets5.4 
Total assets acquired135.1 
Current liabilities(1.2)
Deferred income taxes(18.7)
Other noncurrent liabilities(4.9)
Net assets acquired
$110.3 

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
TotalWeighted Average Life
Trade names$5.2 15
Customer relationships29.3 12
Unpatented technology11.1 11
Acquired intangible assets$45.6 

2022 Acquisitions

Nexsight

On February 28, 2022, the Company acquired Nexsight in a partial stock and partial asset acquisition. Nexsight complements and creates synergies with the Company’s existing iPEK and ADS business units that design and create sewer crawlers, inspection and monitoring systems and software applications that allow teams to identify, anticipate and correct wastewater system issues remotely. Headquartered in Randolph, New Jersey, Nexsight operates in the Company’s Water reporting unit within the Fluid & Metering Technologies (“FMT”) segment. Nexsight was acquired for cash consideration of $112.5 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $54.7 million and $49.8 million, respectively. The goodwill is partially deductible for tax purposes.

The Company finalized the allocation of the purchase price for the Nexsight acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.


7

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

Total
Current assets, net of cash acquired$16.6 
Property, plant and equipment2.0 
Goodwill54.7 
Intangible assets49.8 
Other noncurrent assets4.3 
Total assets acquired127.4 
Current liabilities(9.2)
Deferred income taxes(1.9)
Other noncurrent liabilities(3.8)
Net assets acquired
$112.5 

Acquired intangible assets consist of trade names, customer relationships and software. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
TotalWeighted Average Life
Trade names$13.5 15
Customer relationships31.5 10
Software4.8 5
Acquired intangible assets$49.8 

KZValve

On May 2, 2022, the Company acquired KZValve in an asset acquisition. KZValve is a leading manufacturer of electric valves and controllers used primarily in agricultural applications. KZValve augments and expands IDEX’s agricultural portfolio, complementing Banjo’s current fluid management solutions for these applications. Headquartered in Greenwood, Nebraska, KZValve operates in the Company’s Agriculture reporting unit within the FMT segment. KZValve was acquired for cash consideration of $120.1 million. The entire purchase was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $56.4 million and $52.0 million, respectively. The goodwill is deductible for tax purposes.

The Company finalized the allocation of the purchase price for the KZValve acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.


8

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
Total
Current assets, net of cash acquired$9.7 
Property, plant and equipment1.8 
Goodwill56.4 
Intangible assets52.0 
Deferred income taxes0.2 
Other noncurrent assets1.0 
Total assets acquired121.1 
Current liabilities(1.0)
Net assets acquired
$120.1 

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
TotalWeighted Average Life
Trade names$7.5 15
Customer relationships36.0 13
Unpatented technology 8.5 10
Acquired intangible assets$52.0 

Muon Group

On November 18, 2022, the Company acquired the stock of Muon Group. Muon Group manufactures highly precise flowpaths in a variety of materials that enable the movement of various liquids and gases in critical applications for medical, semiconductor, food processing, digital printing and filtration technologies. Muon Group maintains operations in Hapert, the Netherlands; Eerbeek, the Netherlands; Wijchen, the Netherlands; Dorset, United Kingdom and Pune, India and operates in the Company’s Scientific Fluidics & Optics reporting unit within the HST segment. Muon Group was acquired for cash consideration of $713.0 million. The purchase price was funded with $342.6 million of cash on hand, $170.4 million of proceeds from the Company's Revolving Credit Facility and $200.0 million of proceeds from the Company's Term Facility. Goodwill and intangible assets recognized as part of this transaction were $394.4 million and $319.1 million, respectively. The goodwill is not deductible for tax purposes.

The Company made a preliminary allocation of the purchase price for the Muon Group acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.


9

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

Total
Current assets, net of cash acquired$52.0 
Property, plant and equipment59.1 
Goodwill394.4 
Intangible assets319.1 
Other noncurrent assets9.6 
Total assets acquired834.2 
Current liabilities(26.7)
Deferred income taxes(83.8)
Other noncurrent liabilities(10.7)
Net assets acquired
$713.0 

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
TotalWeighted Average Life
Trade names$38.3 15
Customer relationships212.4 13
Unpatented technology 68.4 11
Acquired intangible assets$319.1 

Acquisition-Related Costs

The Company incurred $1.8 million and $5.4 million of acquisition-related costs during the three and nine months ended September 30, 2023, respectively, and $2.7 million and $5.3 million of acquisition-related costs during the three and nine months ended September 30, 2022, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed, pending and potential acquisitions, including those that ultimately were not completed.

The Company also recorded a $1.2 million fair value inventory step-up charge associated with the completed 2023 acquisition of Iridian in Cost of sales during the three and nine months ended September 30, 2023, and $0.1 million and $0.3 million of fair value inventory step-up charges associated with the completed 2022 acquisitions of Nexsight and KZValve, respectively, in Cost of sales during the nine months ended September 30, 2022.

Divestitures

The Company periodically reviews its businesses for their strategic fit within its core businesses and customers and may from time to time sell various businesses or assets for a variety of reasons. Any resulting gain or loss recognized due to divestitures is recorded within Gain on sale of business in the Condensed Consolidated Statements of Income.

On August 3, 2023, the Company completed the sale of Micropump for proceeds of $110.3 million, net of cash remitted, resulting in a pre-tax gain on the sale of $93.8 million. The divestiture resulted in $22.7 million of income tax expense in the Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2023. Micropump was its own reporting unit and its results were reported within the HST segment.

On September 9, 2022, the Company completed the sale of Knight for proceeds of $49.4 million, net of cash remitted, resulting in a pre-tax gain on the sale of $34.8 million. The divestiture resulted in $5.5 million of income tax expense in the
10

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2022. The results of Knight were reported in the Water reporting unit within the FMT segment.

3. Collaborative Investments

During 2021 and 2022, a subsidiary of IDEX funded a total of $7.2 million in promissory notes as an investment in a start-up company that provides communication technology to improve individual performance and team coordination for firefighters’ responses, which aligns with IDEX’s Fire & Safety/Diversified Products (“FSDP”) segment’s strategic plan. On a quarterly basis, the Company evaluates whether an allowance for credit losses is required for these promissory notes and measures the allowance using the current expected credit loss model. While the Company continues to retain certain convertible equity rights as well as a secured interest in the intellectual property of the start-up company, during the second quarter of 2023, IDEX concluded it would not provide additional funding to the start-up at that time. As a result of the Company’s analysis of the recoverability of its investment during the second quarter of 2023, IDEX determined that its investment may no longer be recoverable. As a result, IDEX recorded a credit loss of $7.7 million in Other expense (income) - net in the Condensed Consolidated Statements of Income and a reserve in Other noncurrent assets on the Condensed Consolidated Balance Sheets for the full amount of the principal and accrued interest outstanding.

4.    Business Segments

IDEX has three reportable business segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”).

The FMT segment designs, produces and distributes positive displacement pumps, valves, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries. FMT application-specific pump and metering solutions serve a diverse range of end markets, including industrial infrastructure (fossil fuels, refined and alternative fuels and water and wastewater), energy, chemical processing, agriculture, food and beverage, semiconductor, pulp and paper, automotive/transportation, plastics and resins, electronics and electrical, construction and mining, pharmaceutical and biopharmaceutical, machinery and numerous other specialty niche markets.

The HST segment designs, produces and distributes a wide range of precision fluidics, positive displacement pumps, powder and liquid processing technologies, drying systems, micro-precision components, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, laboratory and commercial equipment and precision photonic solutions. HST serves a variety of end markets, including food and beverage, life sciences, analytical instruments, pharmaceutical and biopharmaceutical, industrial, semiconductor, automotive/transportation, medical/dental, energy, cosmetics, marine, chemical, wastewater and water treatment, research and aerospace/defense markets.

The FSDP segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications in the automotive, energy and industrial markets and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses in the paint and industrial markets around the world.

Information on the Company’s business segments is presented below based on the nature of the products and services offered. The Company uses Adjusted EBITDA as its principal measure of segment performance. Intersegment sales are contracted with terms equivalent to those of an arm’s-length transaction.






11

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Net sales
Fluid & Metering Technologies
External customers$300.5 $307.4 $945.7 $878.8 
Intersegment sales0.6 0.2 2.3 0.7 
Total segment sales301.1 307.6 948.0 879.5 
Health & Science Technologies
External customers312.7 344.3 1,001.4 984.3 
Intersegment sales0.5 0.7 2.3 1.9 
Total segment sales313.2 345.0 1,003.7 986.2 
Fire & Safety/Diversified Products
External customers180.2 172.3 537.9 508.1 
Intersegment sales0.4 0.1 1.9 0.2 
Total segment sales180.6 172.4 539.8 508.3 
Intersegment eliminations(1.5)(1.0)(6.5)(2.8)
Net sales$793.4 $824.0 $2,485.0 $2,371.2 
ADJUSTED EBITDA
Fluid & Metering Technologies$103.6 $104.4 $323.9 $287.8 
Health & Science Technologies84.4 101.4 278.8 304.8 
Fire & Safety/Diversified Products52.8 47.8 157.0 137.3 
Segment Adjusted EBITDA240.8 253.6 759.7 729.9 
Corporate and other(1)
(15.3)(22.2)(63.7)(64.6)
Adjusted EBITDA225.5 231.4 696.0 665.3 
Interest expense(13.7)(9.6)(40.1)(28.6)
Depreciation(14.7)(12.3)(41.9)(37.0)
Amortization(23.8)(17.0)(70.6)(49.2)
Fair value inventory step-up charges(1.2)— (1.2)(0.4)
Restructuring expenses and asset impairments(4.1)— (8.2)(2.8)
Net impact from the exit of a COVID-19 testing application(2)
— 1.1 — 1.1 
Gain on sale of business93.8 34.8 93.8 34.8 
Gains on sales of assets— — — 2.7 
Credit loss on note receivable from collaborative partner(3)
— — (7.7)— 
Income before income taxes$261.8 $228.4 $620.1 $585.9 

(1) Corporate expenses that can be identified with a segment have been included in determining segment results. The remainder is included in Corporate and Other.
(2) Represents the net impact of the acceleration of previously deferred revenue of $17.9 million and an impairment charge of $16.8 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in the HST segment in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.
(3) Represents a reserve recorded on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.

12

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
September 30, 2023December 31, 2022
ASSETS
Fluid & Metering Technologies$1,700.0 $1,676.9 
Health & Science Technologies2,997.3 2,931.1 
Fire & Safety/Diversified Products797.2 771.8 
Corporate and other175.1 132.1 
Total assets$5,669.6 $5,511.9 

5.    Revenue

Disaggregation of Revenue

The Company has a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. The Company disaggregates its revenue from contracts with customers by reporting unit and geographical region for each segment as the Company believes it best depicts how the amount, nature, timing and uncertainty of its revenue and cash flows are affected by economic factors. Revenue was attributed to geographical region based on the location of the customer. The following tables present revenue disaggregated by reporting unit and geographical region.

Revenue by reporting unit for the three and nine months ended September 30, 2023 and 2022 was as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Pumps$94.7 $102.6 $309.0 $304.5 
Water79.8 82.1 261.2 228.1 
Energy53.7 51.3 160.1 144.3 
Agriculture39.2 42.1 117.9 112.5 
Valves33.7 29.5 99.8 90.1 
Intersegment elimination(0.6)(0.2)(2.3)(0.7)
Fluid & Metering Technologies300.5 307.4 945.7 878.8 
Scientific Fluidics & Optics(1)
162.1 172.4 509.7 462.8 
Performance Pneumatic Technologies60.0 64.1 195.4 191.2 
Sealing Solutions59.2 64.9 186.3 203.1 
Material Processing Technologies29.7 34.6 90.4 103.1 
Micropump(2)
2.2 9.0 21.9 26.0 
Intersegment elimination(0.5)(0.7)(2.3)(1.9)
Health & Science Technologies312.7 344.3 1,001.4 984.3 
Fire & Safety112.0 100.6 328.0 296.1 
Dispensing41.9 42.8 122.8 128.2 
BAND-IT26.7 29.0 89.0 84.0 
Intersegment elimination(0.4)(0.1)(1.9)(0.2)
Fire & Safety/Diversified Products180.2 172.3 537.9 508.1 
Net sales$793.4 $824.0 $2,485.0 $2,371.2 
13

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
(1) The three and nine months ended September 30, 2022 include the acceleration of previously deferred revenue of $17.9 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application. See Note 12 for further detail.

(2) Revenue from Micropump (sold on August 3, 2023) has been included in the Company’s Condensed Consolidated Statements of Income through the date of disposition. See Note 2 for further detail.

Revenue by geographical region for the three and nine months ended September 30, 2023 and 2022 was as follows:

Three Months Ended September 30, 2023
FMTHSTFSDPIDEX
U.S.$168.4 $139.2 $94.4 $402.0 
North America, excluding U.S.15.5 3.2 8.8 27.5 
Europe52.3 106.0 39.0 197.3 
Asia43.1 57.8 29.0 129.9 
Other(1)
21.8 7.0 9.4 38.2 
Intersegment elimination(0.6)(0.5)(0.4)(1.5)
Net sales$300.5 $312.7 $180.2 $793.4 
Three Months Ended September 30, 2022
FMTHSTFSDPIDEX
U.S.(2)
$178.4 $175.0 $93.5 $446.9 
North America, excluding U.S.20.4 3.3 8.4 32.1 
Europe(2)
47.2 93.0 36.8 177.0 
Asia39.1 67.4 25.4 131.9 
Other(1)
22.5 6.3 8.3 37.1 
Intersegment elimination(0.2)(0.7)(0.1)(1.0)
Net sales$307.4 $344.3 $172.3 $824.0 
Nine Months Ended September 30, 2023
FMTHSTFSDPIDEX
U.S.$525.9 $437.3 $280.5 $1,243.7 
North America, excluding U.S.52.8 16.6 25.4 94.8 
Europe163.0 338.1 126.1 627.2 
Asia137.0 189.6 80.4 407.0 
Other(1)
69.3 22.1 27.4 118.8 
Intersegment elimination(2.3)(2.3)(1.9)(6.5)
Net sales$945.7 $1,001.4 $537.9 $2,485.0 
14

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Nine Months Ended September 30, 2022
FMTHSTFSDPIDEX
U.S.(2)
$498.9 $484.7 $255.0 $1,238.6 
North America, excluding U.S.54.3 20.3 27.8 102.4 
Europe(2)
147.7 276.8 123.8 548.3 
Asia116.8 187.0 75.4 379.2 
Other(1)
61.8 17.4 26.3 105.5 
Intersegment elimination(0.7)(1.9)(0.2)(2.8)
Net sales$878.8 $984.3 $508.1 $2,371.2 

(1) Other includes: South America, Middle East, Australia and Africa.

(2) The HST segment includes the acceleration of $17.9 million of previously deferred revenue related to a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application, of which $9.5 million was recognized in the U.S. and $8.4 million was recognized in Europe in both the three and nine months ended September 30, 2022. See Note 12 for further detail.

Performance Obligations

A majority of the Company's contracts have a single performance obligation which represents, in most cases, the product being sold to the customer. Some contracts include multiple performance obligations such as a product and the related installation, extended warranty, software and/or maintenance services. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation.

The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. For performance obligations satisfied at a point in time, revenue is recognized when control transfers to the customer, typically upon shipment. For performance obligations in which the Company transfers control of a product or service over time, revenue is recognized over time as work is performed. Typically, this results when the Company performs services over time or the Company creates a product with no alternative use and has an enforceable right to payment for its performance to date. Revenue from products and services transferred to customers at a point in time and over time was as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Revenue from products transferred at a point in time95 %96 %95 %96 %
Revenue from products and services transferred over time5 %4 %5 %4 %

Contract Balances

The timing of billings and cash collections can result in customer receivables, billings in excess of revenue recognized, advance payments or deposits. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables on the Condensed Consolidated Balance Sheets.

The composition of customer receivables was as follows:
September 30, 2023December 31, 2022
Billed receivables$413.4 $421.3 
Unbilled receivables9.4 10.0 
Total customer receivables$422.8 $431.3 

15

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Billings in excess of revenue recognized, advance payments and deposits represent contract liabilities and are included in deferred revenue which is classified as current or noncurrent based on when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets.

The composition of deferred revenue was as follows:
September 30, 2023December 31, 2022
Deferred revenue - current$48.9 $44.7 
Deferred revenue - noncurrent15.8 15.0 
Total deferred revenue$64.7 $59.7 

6.    Earnings Per Common Share

Diluted earnings per common share (“EPS”) attributable to IDEX is computed by dividing Net income attributable to IDEX by the weighted average number of common shares outstanding (basic) plus common stock equivalents outstanding (diluted) for the period. Common stock equivalents consist of restricted stock, performance share units and stock options, which have been included in the calculation of weighted average common shares outstanding using the treasury stock method.

ASC 260, Earnings Per Share, concludes that all outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding shares of restricted stock are participating securities. Accordingly, Diluted EPS attributable to IDEX was computed using the two-class method prescribed by ASC 260.

Basic weighted average common shares outstanding reconciles to diluted weighted average common shares outstanding as follows:

 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Basic weighted average common shares outstanding75.6 75.4 75.6 75.8 
Dilutive effect of restricted stock, performance share units and stock options0.3 0.4 0.3 0.3 
Diluted weighted average common shares outstanding75.9 75.8 75.9 76.1 

Options to purchase shares of common stock that were not included in the computation of Diluted EPS attributable to IDEX because the effect of their inclusion would have been antidilutive were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Antidilutive shares not included in Diluted EPS attributable to IDEX0.20.50.20.5

16

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
7.    Balance Sheet Components
 September 30, 2023December 31, 2022
INVENTORIES
Raw materials and component parts$289.7 $301.2 
Work in process47.0 54.3 
Finished goods109.9 115.4 
Inventories - net$446.6 $470.9 
ACCRUED EXPENSES
Payroll and related items$91.7 $102.7 
Management incentive compensation9.7 26.4 
Income taxes payable17.9 30.2 
Insurance10.6 11.2 
Warranty8.0 8.1 
Deferred revenue48.9 44.7 
Lease liability21.0 21.6 
Restructuring3.4 1.4 
Accrued interest13.6 5.5 
Pension and retiree medical obligations3.3 3.3 
Other33.9 34.0 
Accrued expenses$262.0 $289.1 
OTHER NONCURRENT LIABILITIES
Pension and retiree medical obligations$53.4 $55.1 
Transition tax payable5.0 9.1 
Deferred revenue15.8 15.0 
Lease liability96.9 96.6 
Other23.7 20.0 
Other noncurrent liabilities$194.8 $195.8 

8.    Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended September 30, 2023, by reportable business segment, were as follows:

FMTHSTFSDPIDEX
Goodwill$800.9 $1,644.8 $393.0 $2,838.7 
   Accumulated goodwill impairment losses(20.7)(149.8)(30.1)(200.6)
Balance at January 1, 2023780.2 1,495.0 362.9 2,638.1 
Foreign currency translation(1.3)(6.1)(1.3)(8.7)
Acquisitions— 53.6 — 53.6 
Measurement period adjustments(1.8)3.3 — 1.5 
Divestitures— (7.2)— (7.2)
Balance at September 30, 2023$777.1 $1,538.6 $361.6 $2,677.3 

ASC 350, Goodwill and Other Intangible Assets, requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce
17

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
the fair value of the reporting unit below its carrying value. In the first nine months of 2023, there were no events or circumstances that would have required an interim impairment test. Annually, on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. Based on the results of the Company’s annual impairment test at October 31, 2022, all reporting units had fair values in excess of their carrying values.

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at September 30, 2023 and December 31, 2022:

 At September 30, 2023At December 31, 2022
 Gross
Carrying
Amount		Accumulated
Amortization		NetWeighted
Average
Life		Gross
Carrying
Amount		Accumulated
Amortization		Net
Amortized intangible assets:
Patents$2.8 $(2.0)$0.8 12$2.9 $(1.8)$1.1 
Trade names180.8 (71.5)109.3 15186.5 (71.4)115.1 
Customer relationships793.7 (225.0)568.7 13772.2 (184.9)587.3 
Unpatented technology210.5 (63.9)146.6 12207.1 (57.8)149.3 
Software4.8 (1.5)3.3 54.8 (0.7)4.1 
Total amortized intangible assets1,192.6 (363.9)828.7 1,173.5 (316.6)856.9 
Indefinite-lived intangible assets:
Banjo trade name62.1 — 62.1 62.1 — 62.1 
Akron Brass trade name28.8 — 28.8 28.8 — 28.8 
Total intangible assets$1,283.5 $(363.9)$919.6 $1,264.4 $(316.6)$947.8 

The Banjo trade name and the Akron Brass trade name are indefinite-lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. Based on the results of the Company’s annual impairment test at October 31, 2022, these indefinite-lived intangible assets had fair values in excess of their carrying values. In the first nine months of 2023, there were no events or circumstances that would have required an interim impairment test on these indefinite-lived intangible assets.

Amortization of intangible assets was $23.8 million and $70.6 million for the three and nine months ended September 30, 2023, respectively. Amortization of intangible assets was $17.0 million and $49.2 million for the three and nine months ended September 30, 2022, respectively. Based on the intangible asset balances as of September 30, 2023, expected amortization expense for the remaining three months of 2023 and for the years 2024 through 2027 is as follows:

Maturity of Intangible AssetsEstimated Amortization
2023 (excluding the nine months ended September 30, 2023)$23.4 
202490.2 
202588.8 
202687.0 
202783.2 

18

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
9.   Borrowings

Borrowings at September 30, 2023 and December 31, 2022 consisted of the following: 

September 30, 2023December 31, 2022
3.20% Senior Notes, due June 2023
$— $100.0 
3.37% Senior Notes, due June 2025
100.0 100.0 
5.13% Senior Notes, due June 2028
100.0 — 
3.00% Senior Notes, due May 2030
500.0 500.0 
2.625% Senior Notes, due June 2031
500.0 500.0 
$800.0 million Revolving Credit Facility, due November 2027(1)
76.9 77.7 
$200.0 million Term Facility, due November 2027(2)
50.0 200.0 
Other borrowings2.5 0.1 
Total borrowings1,329.4 1,477.8 
Less current portion0.7 — 
Less deferred debt issuance costs6.8 7.9 
Less unaccreted debt discount1.1 1.2 
Long-term borrowings$1,320.8 $1,468.7 

(1) At September 30, 2023, there was $76.9 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 2.95% and $7.2 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Credit Facility of approximately $715.9 million.

(2) The Term Facility has a weighted average interest rate of 6.10%. During the third quarter of 2023, the Company repaid $150.0 million of the $200.0 million previously outstanding under the Term Facility.

At September 30, 2023, the Company was in compliance with covenants contained in the credit agreement associated with the Revolving Credit Facility as well as other long-term debt agreements.

Issuance of 5.13% Senior Notes in 2023

On June 13, 2023, the Company completed a private placement of $100 million aggregate principal amount of 5.13% Senior Notes due June 13, 2028 (the “5.13% Senior Notes”) pursuant to a Note Purchase and Master Note Agreement, dated as of June 13, 2023 (the “Purchase Agreement”), among the Company, NYL Investors LLC (“New York Life”) and certain affiliates of New York Life identified as Purchasers of the 5.13% Senior Notes therein. The 5.13% Senior Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company used the proceeds from the 5.13% Senior Notes issuance to repay the 3.20% Senior Notes due June 13, 2023.

The Company may at any time prepay all, or any portion of the 5.13% Senior Notes, provided that such portion is not less than 5% of the aggregate principal amount of all notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. The Company also has the ability to make certain other offers to repurchase any notes outstanding under the Purchase Agreement.

The Purchase Agreement contains certain covenants that restrict the Company’s and its subsidiaries’ ability to, among other things, transfer or sell assets, create liens, incur indebtedness, transact with affiliates and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio, interest coverage ratio and priority debt ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all notes then outstanding under the Purchase Agreement will become due and payable immediately without further action or notice. In the case of payment events of default, any holder of
19

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
such notes affected thereby may declare all of the notes outstanding under the Purchase Agreement held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the notes then outstanding under the Purchase Agreement may declare all of such notes to be due and payable immediately, in each case subject to certain cure and notice provisions.

10.    Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

•Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheets at September 30, 2023 and December 31, 2022:

Basis of Fair Value Measurements
 September 30, 2023December 31, 2022
 Level 1Level 1
Trading securities - mutual funds held in nonqualified SERP(1)
$9.1 $7.5 
Available-for-sale securities - equities(2)
24.6 — 

(1) The Supplemental Executive Retirement Plan (“SERP”) investment assets are offset by a SERP liability which represents the Company’s obligation to distribute SERP funds to participants.

(2) At September 30, 2023, the securities are included in Other current assets on the Company’s Condensed Consolidated Balance Sheets and are available for overnight cash settlement, if necessary, to fund current operations.

There were no transfers of assets or liabilities between Level 1 and Level 2 during the three and nine months ended September 30, 2023 or the year ended December 31, 2022.

The carrying values of the Company’s cash and cash equivalents, accounts receivable, marketable securities, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments.

The following table provides the fair value of the outstanding indebtedness described in Note 9, which is based on quoted market prices and current market rates for debt with similar credit risk and maturity, as well as the carrying value. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to the Company’s rating.

September 30, 2023December 31, 2022
Fair ValueCarrying AmountFair ValueCarrying Amount
Total Borrowings, less deferred debt issuance costs$1,135.4 $1,328.3 $1,328.7 $1,476.6 

20

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
11.    Leases

The Company has commitments under operating leases for certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles used in its operations. Leases with an initial term of 12 months or less are not recorded on the balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Certain leases can include one or more options to renew. The exercise of lease renewal options is at the Company’s sole discretion. The Company does not include renewal periods in any of the leases’ terms until the renewal is executed as they are generally not reasonably certain of being exercised. The Company does not have any material purchase options.

Certain of the Company’s lease agreements contain provisions for future rent increases or have rental payments that are adjusted periodically for inflation or based on usage. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company does not have any significant leases that have not yet commenced.

Supplemental balance sheet information related to leases as of September 30, 2023 and December 31, 2022 was as follows:

Balance Sheet CaptionSeptember 30, 2023December 31, 2022
Right-of-Use (“ROU”) Assets:
Building ROU assets - netOther noncurrent assets$106.3 $104.4 
Equipment ROU assets - netOther noncurrent assets6.5 5.6 
Total ROU assets - net$112.8 $110.0 
Lease Liabilities:
Current lease liabilitiesAccrued expenses$21.0 $21.6 
Noncurrent lease liabilitiesOther noncurrent liabilities96.9 96.6 
Total lease liabilities$117.9 $118.2 

The components of lease cost for the three and nine months ended September 30, 2023 and 2022 were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Fixed lease cost (1)
$8.5 $11.4 $24.2 $27.8 
Variable lease cost0.6 0.6 1.9 1.8 
Total lease cost$9.1 $12.0 $26.1 $29.6 

(1) Includes short-term leases, which are immaterial.

Supplemental cash flow information related to leases for the nine months ended September 30, 2023 and 2022 was as follows:

Nine Months Ended September 30,
20232022
Cash paid for amounts included in the measurement of lease liabilities$24.8 $28.1 
Right-of-use assets obtained in exchange for new lease liabilities17.6 7.1 
21

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Other supplemental information related to leases as of September 30, 2023 and December 31, 2022 was as follows:

Lease Term and Discount RateSeptember 30, 2023December 31, 2022
Weighted-average remaining lease term (years):
Building and equipment7.147.43
Vehicles2.612.14
Weighted-average discount rate:
Building and equipment3.68 %3.41 %
Vehicles2.81 %1.70 %

The Company uses its incremental borrowing rate to determine the present value of the lease payments.

Total lease liabilities at September 30, 2023 have scheduled maturities as follows:
Maturity of Lease Liabilities
2023 (excluding the nine months ended September 30, 2023)$6.4 
202419.6 
202522.3 
202619.5 
202715.5 
Thereafter52.0 
Total lease payments135.3 
Less: Imputed interest(17.4)
Present value of lease liabilities$117.9 

12.    Restructuring Expenses and Asset Impairments

From time to time, the Company incurs expenses to facilitate long-term sustainable growth through cost reduction actions, consisting of employee reductions, facility rationalization and contract termination costs. These costs include severance costs, exit costs and asset impairments and are included in Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consist of lease exit and contract termination costs.

2023 Initiative

During the three and nine months ended September 30, 2023, the Company incurred severance costs related to employee reductions in conjunction with cost mitigation efforts as a result of current market conditions, contract termination costs and asset impairments.


22

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Pre-tax restructuring expenses and asset impairments by segment for the three and nine months ended September 30, 2023 were as follows:

Three Months Ended September 30, 2023
Severance CostsExit CostsAsset ImpairmentsTotal
Fluid & Metering Technologies$0.8 $0.6 $0.3 $1.7 
Health & Science Technologies1.5 — — 1.5 
Fire & Safety/Diversified Products0.4 — — 0.4 
Corporate/Other0.5 — — 0.5 
Restructuring expenses and asset impairments$3.2 $0.6 $0.3 $4.1 

Nine Months Ended September 30, 2023
Severance CostsExit CostsAsset ImpairmentsTotal
Fluid & Metering Technologies$1.0 $0.6 $0.8 $2.4 
Health & Science Technologies4.5 — — 4.5 
Fire & Safety/Diversified Products0.8 — — 0.8 
Corporate/Other0.5 — — 0.5 
Restructuring expenses and asset impairments$6.8 $0.6 $0.8 $8.2 

2022 Initiative

During the three and nine months ended September 30, 2022, the restructuring costs incurred by the Company primarily related to asset impairments. In addition, the Company also incurred severance costs related to employee reductions.

In the second quarter of 2020, the Company engaged in the development of a COVID-19 testing application with a customer at one of the Company’s businesses in the HST segment. As part of this contract, the customer fully funded the $28.7 million investment needed to complete the development and production of microfluidic cartridges during 2020 and 2021. The costs incurred by the Company were primarily recorded as Property, plant and equipment – net in the Condensed Consolidated Balance Sheets and were being depreciated over the expected life of the assets, while the reimbursement was recorded as Deferred revenue in the Condensed Consolidated Balance Sheets and was being recognized as units were shipped.

In the third quarter of 2022, the Company was informed by the customer of its decision to discontinue further investment in commercializing its COVID-19 testing application. This event was deemed a triggering event, which required an interim impairment test be performed on the Property, plant and equipment related to this contract, resulting in an impairment charge of $16.8 million that was recorded as Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income during three and nine months ended September 30, 2022. In addition, the Company accelerated previously deferred revenue of $17.9 million related to units that are no longer expected to be shipped and recorded it as Net sales in the Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2022.


23

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Pre-tax restructuring expenses and asset impairments by segment for the three and nine months ended September 30, 2022 were as follows:

Three Months Ended September 30, 2022
Severance CostsExit CostsAsset ImpairmentsTotal
Fluid & Metering Technologies$0.1 $— $— $0.1 
Health & Science Technologies0.4 — 16.8 17.2 
Fire & Safety/Diversified Products0.4 — — 0.4 
Corporate/Other— — — — 
Restructuring expenses and asset impairments$0.9 $— $16.8 $17.7 

Nine Months Ended September 30, 2022
Severance CostsExit CostsAsset ImpairmentsTotal
Fluid & Metering Technologies$1.6 $0.3 $0.2 $2.1 
Health & Science Technologies0.6 — 16.8 17.4 
Fire & Safety/Diversified Products1.4 — — 1.4 
Corporate/Other0.2 — — 0.2 
Restructuring expenses and asset impairments$3.8 $0.3 $17.0 $21.1 

Restructuring accruals reflected in Accrued expenses in the Company’s Condensed Consolidated Balance Sheets are as follows:
Restructuring Initiatives
Balance at January 1, 2023$1.4 
Restructuring expenses7.4 
Payments, utilization and other(5.4)
Balance at September 30, 2023$3.4 

24

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
13.    Other Comprehensive Loss

The components of Other comprehensive loss are as follows:

 Three Months Ended September 30, 2023Three Months Ended September 30, 2022
 Pre-taxTaxNet of taxPre-taxTaxNet of tax
Cumulative translation adjustment$(58.1)$— $(58.1)$(94.9)$— $(94.9)
Pension and other postretirement adjustments(0.3)— (0.3)0.6 — 0.6 
Total other comprehensive loss$(58.4)$— $(58.4)$(94.3)$— $(94.3)

 Nine Months Ended September 30, 2023Nine Months Ended September 30, 2022
 Pre-taxTaxNet of taxPre-taxTaxNet of tax
Cumulative translation adjustment$(19.2)$— $(19.2)$(196.3)$— $(196.3)
Pension and other postretirement adjustments(1.0)0.2 (0.8)2.5 (0.7)1.8 
Total other comprehensive loss$(20.2)$0.2 $(20.0)$(193.8)$(0.7)$(194.5)

The amounts reclassified from Accumulated other comprehensive loss to Net income during the three and nine months ended September 30, 2023 and 2022 are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022Income Statement Caption
Pension and other postretirement plans:
Amortization of actuarial (gains) losses and prior service costs$(0.3)$0.6 $(1.0)$2.5 Other (income) expense - net
Total before tax(0.3)0.6 (1.0)2.5 
Provision for income taxes— — 0.2 (0.7)
Total net of tax$(0.3)$0.6 $(0.8)$1.8 

14.    Share Repurchases

On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorization of the Board of Directors of $300.0 million on December 1, 2015. These authorizations have no expiration date. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Credit Facility. During the nine months ended September 30, 2023, the Company repurchased a total of 5,400 shares at a cost of $1.1 million. During the nine months ended September 30, 2022, the Company repurchased a total of 788,623 shares at a cost of $146.3 million, of which $0.5 million was settled in October 2022. As of September 30, 2023, the amount of share repurchase authorization remaining was $562.8 million.

15.   Share-Based Compensation

The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on the recommendation from the Compensation Committee.

The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Condensed Consolidated Statements of Income is consistent with the classification of cash compensation for the same employees.

25

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Stock Options

Stock options granted under the Company’s plans are generally non-qualified and are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. The fair value of each option grant was estimated on the date of the grant using the Black Scholes valuation model. Stock options generally vest ratably over four years, with vesting beginning one year from the date of grant, and generally expire 10 years from the date of grant. The service period for certain retiree eligible participants is accelerated. Weighted average stock option fair values and assumptions for the periods presented are disclosed below.

 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Weighted average fair value of grants$56.47$52.91$60.49$41.90
Dividend yield1.20%1.16%1.07%1.14%
Volatility26.78%25.99%27.17%25.16%
Risk-free interest rate
4.26%
3.35%
4.12%
1.87%
Expected life (in years)4.504.904.504.90

Total compensation cost for stock options is recorded in the Condensed Consolidated Statements of Income as follows:

 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Cost of sales$0.1 $0.1 $0.5 $0.4 
Selling, general and administrative expenses(1)
1.0 0.7 8.2 6.6 
Total expense before income taxes1.1 0.8 8.7 7.0 
Income tax benefit(0.2)(0.1)(0.8)(0.6)
Total expense after income taxes$0.9 $0.7 $7.9 $6.4 

(1) The three months ended September 30, 2023 include $0.4 million of higher expense due to timing of accelerated stock compensation costs for retiree eligible participants, net of $0.2 million of executive forfeitures compared with the same period in 2022. The nine months ended September 30, 2023 include $1.5 million of higher expense compared with the same period in 2022 as it relates to the timing of accelerated stock compensation costs for retiree eligible participants.

A summary of the Company’s stock option activity as of September 30, 2023 and changes during the nine months ended September 30, 2023 are presented in the following table:
Stock OptionsSharesWeighted
Average
Price		Weighted-Average
Remaining
Contractual Term		Aggregate
Intrinsic
Value
(Dollars in millions except weighted average price)
Outstanding at January 1, 20231,015,572 $161.45 6.94$67.9 
Granted225,115 224.90 
Exercised(87,217)143.37 
Forfeited(71,833)200.60 
Outstanding at September 30, 20231,081,637 $173.52 6.82$40.9 
Vested and expected to vest as of September 30, 20231,048,823 $172.37 6.76$40.7 
Exercisable at September 30, 2023595,028 $148.02 5.44$35.8 

As of September 30, 2023, there was $10.0 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.5 years.

26

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Restricted Stock

Restricted stock awards generally cliff vest after three years for employees and non-employee directors. The service period for certain retiree eligible participants is accelerated. Unvested restricted stock carries dividend and voting rights and the sale of the shares is restricted prior to the date of vesting. Dividends are paid on restricted stock awards and their fair value is equal to the market price of the Company’s stock at the date of the grant. A summary of the Company’s restricted stock activity as of September 30, 2023 and changes during the nine months ended September 30, 2023 are presented in the following table:

Restricted StockSharesWeighted-Average
Grant Date Fair
Value
Unvested at January 1, 2023104,382 $179.45 
Granted41,075 219.72 
Vested(22,992)173.91 
Forfeited(12,220)201.97 
Unvested at September 30, 2023110,245 $193.11 

Total compensation cost for restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:

 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Cost of sales$0.1 $— $0.4 $0.2 
Selling, general and administrative expenses(1)
1.0 2.2 4.0 5.4 
Total expense before income taxes1.1 2.2 4.4 5.6 
Income tax benefit(0.2)(0.4)(0.9)(1.0)
Total expense after income taxes$0.9 $1.8 $3.5 $4.6 

(1) The three and nine months ended September 30, 2023 include $1.1 million and $0.6 million, respectively, of lower expense due to timing of accelerated stock compensation costs for retiree eligible participants compared with the same period in 2022.

As of September 30, 2023, there was $7.3 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.1 years.

Cash-Settled Restricted Stock

The Company also maintains a cash-settled share-based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years. The service period for certain retiree eligible participants is accelerated. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. Dividend equivalents are paid on certain cash-settled restricted stock awards. A summary of the Company’s unvested cash-settled restricted stock activity as of September 30, 2023 and changes during the nine months ended September 30, 2023 are presented in the following table:

27

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Cash-Settled Restricted StockSharesWeighted-Average
Fair Value
Unvested at January 1, 202357,356 $228.33 
Granted20,705 225.34 
Vested(15,981)229.03 
Forfeited(3,420)208.02 
Unvested at September 30, 202358,660 $208.02 

Total compensation cost for cash-settled restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Cost of sales$— $— $0.2 $— 
Selling, general and administrative expenses0.6 1.1 2.1 1.1 
Total expense before income taxes0.6 1.1 2.3 1.1 
Income tax benefit— — (0.1)— 
Total expense after income taxes$0.6 $1.1 $2.2 $1.1 

As of September 30, 2023, there was $4.8 million of total unrecognized compensation cost related to cash-settled restricted shares that is expected to be recognized over a weighted-average period of 1.1 years.

Performance Share Units

Weighted average performance share unit fair values and assumptions for the periods specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.
 Nine Months Ended September 30,
20232022
Weighted average fair value of grants$308.18$235.54
Dividend yield—%—%
Volatility27.00%28.09%
Risk-free interest rate4.37%1.73%
Expected life (in years)2.942.93

A summary of the Company’s performance share unit activity as of September 30, 2023 and changes during the nine months ended September 30, 2023 are presented in the following table:
Performance Share UnitsSharesWeighted-Average
Grant Date Fair
Value
Unvested at January 1, 202370,915 $236.66 
Granted28,030 308.18 
Vested(18,105)226.86 
Forfeited(12,050)262.44 
Unvested at September 30, 202368,790 $265.22 

On January 31, 2023, 18,105 performance share units vested. Based on the Company’s relative total shareholder return rank during the three year period ended January 31, 2023, the Company achieved a 173% payout factor and issued 31,334 common shares in February 2023 for awards that vested in 2023.
28

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

Total compensation cost for performance share units is recorded in the Condensed Consolidated Statements of Income as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Cost of sales$— $— $— $— 
Selling, general and administrative expenses(1)
(0.3)0.2 5.7 4.0 
Total expense before income taxes(0.3)0.2 5.7 4.0 
Income tax benefit(0.1)— (0.3)(0.1)
Total expense after income taxes$(0.4)$0.2 $5.4 $3.9 

(1) The three months ended September 30, 2023 include $1.0 million of lower expense due to executive forfeitures, net of $0.4 million of higher expense due to timing of accelerated stock compensation costs for retiree eligible participants compared with the same period in 2022. The nine months ended September 30, 2023 include $2.0 million of higher expense as it relates to the timing of accelerated stock compensation costs for retiree eligible participants, net of $0.7 million of executive forfeitures when compared with the same period in 2022.

As of September 30, 2023, there was $3.1 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.1 years.

16.   Retirement Benefits

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans as well as other post-retirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.

 Pension Benefits
 Three Months Ended September 30,
 20232022
 U.S.Non-U.S.U.S.Non-U.S.
Service cost$0.1 $0.3 $— $0.5 
Interest cost0.1 0.6 0.1 0.2 
Expected return on plan assets(0.1)(0.4)(0.1)(0.4)
Net amortization— (0.1)0.1 0.2 
Net periodic cost$0.1 $0.4 $0.1 $0.5 
 Pension Benefits
 Nine Months Ended September 30,
 20232022
 U.S.Non-U.S.U.S.Non-U.S.
Service cost$0.1 $0.9 $0.1 $1.4 
Interest cost0.3 2.0 0.2 0.7 
Expected return on plan assets(0.2)(1.2)(0.2)(1.0)
Net amortization0.1 (0.4)0.2 0.6 
Net periodic cost$0.3 $1.3 $0.3 $1.7 


29

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
 Other Postretirement Benefits
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Service cost$0.1 $0.2 $0.3 $0.5 
Interest cost0.2 0.1 0.6 0.4 
Net amortization(0.2)(0.1)(0.7)(0.3)
Net periodic cost$0.1 $0.2 $0.2 $0.6 

The Company recognizes the service cost component in both Cost of sales and Selling, general and administrative expenses in the Condensed Consolidated Statements of Income depending on the functional area of the underlying employees and the interest cost, expected return on plan assets and net amortization components in Other expense (income) - net in the Condensed Consolidated Statements of Income.

The Company expects to contribute approximately $3.9 million to its defined benefit plans and $1.1 million to its other post-retirement benefit plans in 2023. During the first nine months of 2023, the Company contributed a total of $3.9 million to fund these plans.

17.    Commitments and Contingencies

The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings arising in the ordinary course of business. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.

18.   Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes and the effective tax rates were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Provision for income taxes$52.8 $49.7 $132.8 $129.2 
Effective tax rate20.2 %21.8 %21.4 %22.1 %

The decrease in the effective tax rate for both the three and nine months ended September 30, 2023 is primarily due to the tax benefit related to the finalization of the impact of research expenditure capitalization on the foreign derived intangible income deduction and the reduction of Global Intangible Low-Tax Income (“GILTI”) as a result of the tax amortization of goodwill related to the Muon Group acquisition.
30

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes in this quarterly report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K and under the heading “Cautionary Statement Under the Private Securities Litigation Reform Act” discussed elsewhere in this quarterly report.

This discussion includes certain non-GAAP financial measures that have been defined and reconciled to the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) under the headings “Non-GAAP Disclosures” and “Free Cash Flow.” This discussion also includes Operating working capital, which has been defined under the heading “Liquidity and Capital Resources.” The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

Overview

IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business as well as by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are important factors that influence the demand for IDEX’s products.

Third Quarter Highlights

Select key financial results for the three months ended September 30, 2023 when compared to the same period in the prior year are as follows:
Three Months Ended September 30,
(Dollars in millions, except per share amounts)20232022% / bps Change
Net sales$793.4$824.0(4%)
Adjusted net sales*793.4806.1(2%)
Organic net sales growth*(6%)
Gross profit349.6381.8(8%)
Adjusted gross profit*350.8363.9(4%)
Net income attributable to IDEX209.1178.717%
Adjusted net income attributable to IDEX*160.6161.9(1%)
Adjusted EBITDA*225.5231.4(3%)
Diluted EPS attributable to IDEX2.752.3617%
Adjusted diluted EPS attributable to IDEX*2.122.14(1%)
Cash flows from operating activities226.6198.114%
Free cash flow*206.5181.814%
Gross margin44.1%46.3%(220) bps
Adjusted gross margin*44.2%45.1%(90) bps
Net income margin26.3%21.7%460 bps
Adjusted EBITDA margin*28.4%28.7%(30) bps
*These are non-GAAP measures. See the definitions of these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures under the headings “Non-GAAP Disclosures” and “Free Cash Flow.”

31

During the three months ended September 30, 2023, the Company delivered strong operating performance. While continued customer inventory recalibration, largely within the Company’s Health & Science Technologies segment, resulted in lower sales volumes, the Company realized strong price/cost and achieved favorable operational productivity across its segments. Net income attributable to IDEX also reflects a $71.1 million gain, net of tax, on the divestiture of the Company’s Micropump business, which was sold in August 2023. Cash flow from operating activities was $226.6 million during the quarter, an increase of 14% compared to the same prior year period, driven primarily by inventory reduction efforts. Strong operating cash flow resulted in record free cash flow of $206.5 million during the quarter.

The Company believes its customer destocking efforts are largely complete and expects orders to begin to stabilize and lead times to return to more normalized levels during the fourth quarter of 2023.

Results of Operations
The following is a discussion and analysis of the Company’s results of operations for the three and nine months ended September 30, 2023 compared with the three and nine months ended September 30, 2022.

Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions, except per share amounts)20232022% / bps Change20232022% / bps Change
Net sales$793.4$824.0(4 %)$2,485.0$2,371.25 %
Cost of sales443.8442.2— %1,374.91,290.07 %
Gross profit349.6381.8(8 %)1,110.11,081.23 %
Gross margin44.1 %46.3 %(220) bps44.7 %45.6 %(90) bps
Selling, general and administrative expenses165.9161.92 %529.9483.710 %
Restructuring expenses and asset impairments4.117.7(77 %)8.221.1(61 %)
Operating income179.6202.2(11 %)572.0576.4(1 %)
Gain on sale of business(93.8)(34.8)170 %(93.8)(34.8)170 %
Other (income) expense - net(2.1)(1.0)110 %5.6(3.3)(270 %)
Interest expense13.79.643 %40.128.640 %
Income before income taxes261.8228.415 %620.1585.96 %
Provision for income taxes52.849.76 %132.8129.23 %
Effective tax rate20.2 %21.8 %(160) bps21.4 %22.1 %(70) bps
Net income attributable to IDEX$209.1$178.717 %$487.5$456.97 %
Diluted earnings per common share attributable to IDEX$2.75$2.3617 %$6.42$6.007 %

Net Sales

Net sales for the three months ended September 30, 2023 decreased 4% as compared to the same prior year period. Organic sales decreased 6% driven by the impact of current market conditions on volumes in the Health & Science Technologies businesses, partially offset by price capture across all segments. This decrease, combined with the acceleration of previously deferred revenue related to the exit of a COVID-19 testing application in 2022 that did not reoccur in 2023 (see Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail), was partially offset by acquisition-related growth, net of divestitures, of 3% (see Note 2 in the Notes to Condensed Consolidated Financial Statements for further detail on acquisitions and divestitures) and a favorable impact from foreign currency translation.

Net sales for the nine months ended September 30, 2023 increased 5% as compared to the same prior year period driven by a 5% increase in acquisitions, net of divestitures, and a 1% increase in organic sales. Price capture offset the impact of lower volumes in the Health & Science Technologies segment as well as the acceleration of previously deferred revenue in 2022 that did not reoccur in 2023, both of which are discussed above.

In the three months ended September 30, 2023, net sales decreased 10% domestically and increased 4% internationally, and sales to customers outside the U.S. were approximately 49% of total sales in the third quarter of 2023 compared with 46% during the same period in 2022. In the nine months ended September 30, 2023, net sales were flat domestically and increased 10% internationally, and sales to customers outside the U.S. were approximately 50% of total sales in the first nine months of 2023 compared with 48% during the same period in 2022.
32

Cost of Sales

Cost of sales for both the three and nine months ended September 30, 2023 increased due to acquisitions, net of divestitures, inflation and higher employee-related costs, partially offset by lower sales volume.

Gross Profit and Gross Margin

Gross profit and Gross margin for the three and nine months ended September 30, 2023 were positively impacted by strong operational productivity and price/cost and negatively impacted by lower volume leverage, unfavorable mix and higher employee-related costs. While acquisitions, net of divestitures, as well as the acceleration of previously deferred revenue related to the exit of a COVID-19 testing application in 2022 that did not reoccur in 2023 also positively impacted Gross profit, they resulted in a dilutive impact to overall Gross margin.

Selling, General and Administrative Expenses

Selling, general and administrative expenses in the three months ended September 30, 2023 increased primarily due to the $11.0 million impact from acquisitions, including amortization, net of divestitures. Excluding this impact, selling, general and administrative expenses decreased by $7.0 million as compared with the same prior year period primarily due to lower employee-related costs, including the impact of executive forfeitures recorded during the current year period as well as the timing of retirement eligibility of participants.

Selling, general and administrative expenses in the nine months ended September 30, 2023 increased primarily due to the $40.0 million impact from acquisitions, including amortization, net of divestitures, as well as increases in employee-related costs, which include accelerated stock compensation costs for retiree eligible participants.

Restructuring Expenses and Asset Impairments

Restructuring expenses and asset impairments decreased in both the three and nine months ended September 30, 2023 primarily due to an asset impairment charge of $16.8 million related to the exit of a COVID-19 testing application in 2022, partially offset by higher severance costs in 2023 incurred in conjunction with cost mitigation efforts as a result of current market conditions. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

Gain on Sale of Business

In the third quarter of 2023, the Company completed the sale of Micropump for proceeds of $110.3 million, net of cash remitted, resulting in a pre-tax gain on the sale of $93.8 million. In the third quarter of 2022, the Company completed the sale of Knight for proceeds of $49.4 million, net of cash remitted, resulting in a pre-tax gain on the sale of $34.8 million.

Other (Income) Expense - Net

Other (income) expense - net increased to $2.1 million of income in the three months ended September 30, 2023 compared to $1.0 million of income during the same period in 2022. The increase was primarily due to higher interest earned in 2023.

Other (income) expense - net decreased to $5.6 million of expense in the nine months ended September 30, 2023 compared to $3.3 million of income during the same period in 2022. The increase in expense was primarily due to a $7.7 million credit loss reserve on a note receivable from a collaborative partner (see Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail), higher foreign currency transaction losses and $2.7 million of gains on the sale of assets in 2022 that did not reoccur in 2023, partially offset by higher interest earned in 2023.

Interest Expense

Interest expense for the three and nine months ended September 30, 2023 increased compared to the same period in 2022 due to the borrowings incurred under the Revolving Credit Facility and the Term Facility in connection with the Muon Group acquisition in November 2022 as well as higher interest rates on the Company’s indebtedness.

Income Taxes

The effective tax rates of 20.2% and 21.4% for the three and nine months ended September 30, 2023, respectively, decreased as compared with the effective tax rates of 21.8% and 22.1% during the same periods in 2022 primarily due to the
33

finalization of both research expenditure capitalization on foreign derived income as well as the reduction of tax related to the treatment of the acquisition of Muon Group acquisition.

Results of Reportable Business Segments

The Company has three reportable segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”). For a detailed description of the operations within each segment, refer to Note 4 in the Notes to Condensed Consolidated Financial Statements.

Within its three reportable segments, the Company maintains 12 reporting units where the Company focuses on organic growth and strategic acquisitions. Management’s primary measurements of segment performance are sales, adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Adjusted EBITDA margin.

FMT
HST(1)
FSDP
PumpsScientific Fluidics & OpticsFire & Safety
WaterSealing SolutionsDispensing
EnergyPerformance Pneumatic TechnologiesBAND-IT
ValvesMaterial Processing Technologies
Agriculture

(1) The results of operations of Micropump (sold on August 3, 2023) have been included in the Company’s Condensed Consolidated Statements of Income through the date of disposition.

The table below illustrates the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the three and nine months ended September 30, 2023.

Three Months Ended September 30, 2023Nine Months Ended September 30, 2023
FMTHSTFSDPIDEXFMTHSTFSDPIDEX
Net sales38 %39 %23 %100 %38 %40 %22 %100 %
Adjusted EBITDA(1)
43 %35 %22 %100 %42 %37 %21 %100 %

(1) Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $15.3 million and $63.7 million for the three and nine months ended September 30, 2023, respectively.

Fluid & Metering Technologies Segment

Three Months Ended September 30,Components of Change
(Dollars in millions) 20232022ChangeOrganic
Acq/Div(1)
Foreign CurrencyTotal
Domestic sales$168.4$178.4(6%)
International sales132.7129.23%
Net sales(2)
301.1307.6(2%)(1%)(2%)1%(2%)
Adjusted EBITDA$103.6$104.4(1%)—(1%)—(1%)
Adjusted EBITDA margin34.4 %33.9 %50 bps50 bps——50 bps
34

Nine Months Ended September 30,Components of Change
(Dollars in millions) 20232022Change
Organic(3)
Acq/Div(1)(3)
Foreign CurrencyTotal
Domestic sales$525.9$498.95%
International sales422.1380.611%
Net sales(2)
948.0879.58%6%2%—8%
Adjusted EBITDA$323.9$287.813%11%2%—13%
Adjusted EBITDA margin34.2 %32.7 %150 bps170 bps(20) bps—150 bps

(1) Divestitures included Knight sold in September 2022.

(2) Net sales to customers outside the U.S. were approximately 44% of total segment sales in the third quarter of 2023 compared with 42% during the same period in 2022 and approximately 45% of total segment sales in the first nine months of 2023 compared with 43% during the same period in 2022.

(3) Based on the timing of the acquisitions, Nexsight results for the first three months of 2023 and KZValve results for the first four months of 2023 are reflected in the acquisitions/divestitures column while the remaining year-over-year impact is included in the organic column.

•Organic net sales for both the three and nine months ended September 30, 2023 was positively impacted by the following:
◦Water reporting unit driven by price capture, favorability in the municipal water market, targeted growth performance and operational execution;
◦Energy reporting unit driven by operational execution related to backlog reduction, improved supply chain conditions, price capture and growth initiatives; and
◦Valves reporting unit driven by strong price capture and demand in Asia.
Organic net sales for both the three and nine months ended September 30, 2023 was negatively impacted by the Agriculture reporting unit driven by distribution inventory recalibration, partially offset by positive OEM demand.
In addition, within the Pumps reporting unit, strong price capture only partially offset the impact of softness in the industrial market during the three months ended September 30, 2023, while strong price capture and operational execution more than offset the impact of softness in the industrial market during the nine months ended September 30, 2023.
•The increase in Adjusted EBITDA margin for both the three and nine months ended September 30, 2023 was primarily due to strong price/cost, favorable operational productivity and lower discretionary spending, partially offset by lower volume leverage and higher employee-related costs. In addition, unfavorable mix negatively impacted the nine months ended September 30, 2023.

Health & Science Technologies Segment

Three Months Ended September 30,Components of Change
(Dollars in millions)20232022ChangeOrganic
Acq/Div(1)
Other(2)
Foreign CurrencyTotal
Domestic sales$139.2$175.0(20%)
International sales174.0170.02%
Net sales(3)
313.2345.0(9%)(15%)10%(5%)1%(9%)
Adjusted net sales(4)
313.2327.1(4%)(15%)10%—1%(4%)
Adjusted EBITDA84.4101.4(17%)(25%)8%——(17%)
Adjusted EBITDA margin26.9 %31.0 %(410) bps(370) bps(40) bps——(410) bps

35

Nine Months Ended September 30,Components of Change
(Dollars in millions)20232022ChangeOrganic
Acq/Div(1)
Other(2)
Foreign CurrencyTotal
Domestic sales$437.3$484.7(10%)
International sales566.4501.513%
Net sales(3)
1,003.7986.22%(6%)10%(2%)—2%
Adjusted net sales(4)
1,003.7968.34%(6%)10%——4%
Adjusted EBITDA278.8304.8(9%)(18%)9%——(9%)
Adjusted EBITDA margin27.8 %31.5 %(370) bps(370) bps(10) bps—10 bps(370) bps

(1) Acquisitions included Iridian acquired in May 2023 and Muon Group acquired in November 2022. Divestitures included Micropump sold in August 2023.

(2) Includes the impact of the acceleration of previously deferred revenue of $17.9 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Consolidated Financial Statements for further detail.

(3) Net sales to customers outside the U.S. were approximately 56% of total segment sales in the third quarter of 2023 compared with 49% during the same period in 2022 and approximately 56% of total segment sales in the first nine months of 2023 compared with 51% during the same period in 2022.

(4) Adjusted net sales is a non-GAAP measure. Adjusted net sales is calculated as net sales less the acceleration of previously deferred revenue related to the exit of a COVID-19 testing application. See the reconciliation of adjusted net sales to its most directly comparable financial measure under the heading “Non-GAAP Disclosures.” Adjusted net sales is used in the calculation of Adjusted EBITDA margin for the three and nine months ended September 30, 2022. See Note 12 in the Notes to Consolidated Financial Statements for further detail.
•The decrease in organic net sales for both the three and nine months ended September 30, 2023 was attributed to decreases in the following:
◦Scientific Fluidics & Optics reporting unit driven by lower demand from Analytical Instrumentation and Life Science original equipment manufacturers due to customer inventory recalibration and market slowing, partially offset by price capture;
◦Sealing Solutions reporting unit driven by softness in the semiconductor market; and
◦Material Processing Technologies reporting unit driven by lower demand in the pharma/biopharma and food/nutrition markets, partially offset by operational execution related to backlog reduction and price capture.
In addition, within the Performance Pneumatics Technologies reporting unit, price capture only partially offset the impact of softness in the industrial market during the three months ended September 30, 2023, while targeted growth performance and price capture more than offset the impact of softness in the industrial market during the nine months ended September 30, 2023.
•The decrease in Adjusted EBITDA margin for both the three and nine months ended September 30, 2023 was primarily due to lower volume leverage and unfavorable mix, partially offset by strong price/cost, favorable operational productivity and lower discretionary spending. In addition, higher employee-related costs negatively impacted Adjusted EBITDA during the nine months ended September 30, 2023.














36

Fire & Safety/Diversified Products Segment

Three Months Ended September 30,Components of Change
(Dollars in millions)20232022ChangeOrganicAcq/DivForeign CurrencyTotal
Domestic sales$94.4$93.51%
International sales86.278.99%
Net sales(1)
180.6172.45%3%—2%5%
Adjusted EBITDA52.847.810%8%—2%10%
Adjusted EBITDA margin29.3 %27.8 %150 bps150 bps——150 bps

Nine Months Ended September 30,Components of Change
(Dollars in millions)20232022ChangeOrganicAcq/DivForeign CurrencyTotal
Domestic sales$280.5$255.010%
International sales259.3253.32%
Net sales(1)
539.8508.36%7%—(1%)6%
Adjusted EBITDA157.0137.314%14%——14%
Adjusted EBITDA margin29.1 %27.0 %210 bps210 bps——210 bps

(1) Net sales to customers outside the U.S. were approximately 48% of total segment sales in the third quarter of 2023 compared with 46% during the same period in 2022 and approximately 48% of total segment sales in the first nine months of 2023 compared with 50% during the same period in 2022.

•The change in organic net sales for both the three and nine months ended September 30, 2023 was attributed to an increase in the Fire & Safety reporting unit driven by price capture, continued demand for rescue tools, improved supply chain conditions and operational execution. This increase was partially offset by a decrease in the Dispensing report unit driven by timing of deliveries within Europe and Asia, partially offset by higher North American project sales. In addition, within the BAND-IT reporting unit, continued share gain in an otherwise flat automotive market positively impacted the three months ended September 30, 2023 while a decline in the aerospace and energy markets negatively impacted the three and nine months ended September 30, 2023.
•The increase in Adjusted EBITDA margin for both the three and nine months ended September 30, 2023 was primarily due to strong price/cost and favorable operational productivity, partially offset by unfavorable mix as well as higher employee-related costs and discretionary spending. In addition, lower volume leverage negatively impacted the three months ended September 30, 2023, while higher volume leverage positively impacted the nine months ended September 30, 2023.

37

Liquidity and Capital Resources

Liquidity

Based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Credit Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings.

Select key liquidity metrics at September 30, 2023 are as follows:

(In millions)September 30, 2023
Working capital$1,030.7 
Current ratio3.1 to 1
Cash and cash equivalents$562.7 
Cash held outside of the United States427.7 
Revolving Credit Facility capacity$800.0 
Borrowings76.9 
Letters of credit7.2 
Revolving Credit Facility availability$715.9 

The Company believes that additional borrowings through various financing alternatives remain available, if required.

Operating Working Capital

Operating working capital, calculated as Receivables plus Inventories minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details operating working capital as of September 30, 2023 and December 31, 2022:

(In millions)September 30, 2023December 31, 2022
Receivables$430.6 $442.8 
Inventories446.6 470.9
Less: Trade accounts payable176.3 208.9 
Operating working capital$700.9 $704.8 

Operating working capital decreased $3.9 million to $700.9 million during the nine months ended September 30, 2023. Acquisitions, divestitures and foreign currency translation contributed $3.7 million to the decrease in Operating working capital. Reduced inventory levels were largely offset by lower levels of accounts payable and strong price capture partially offset the impact of lower volume on Receivables.
38

Cash Flow Summary

The following table is derived from the Condensed Consolidated Statements of Cash Flows:

Nine Months Ended September 30,
(In millions)20232022
Net cash flows provided by (used in):
Operating activities$515.7 $390.1 
Investing activities(90.0)(224.4)
Financing activities(286.7)(274.6)

Operating Activities

Cash flows provided by operating activities increased $125.6 million to $515.7 million in the nine months ended September 30, 2023 primarily due to lower investments in working capital in 2023 as a result of efforts to recalibrate inventory levels in response to normalizing market conditions. The prior year period included investments in operating working capital related to higher volumes and increased inventories to support production amid supply chain challenges.

Investing Activities

Cash flows used in investing activities decreased during the nine months ended September 30, 2023 primarily due to the purchase of Iridian in 2023 for $110.3 million as compared with the purchases of Nexsight and KZValve in 2022 for $232.6 million as well as proceeds of $110.3 million in 2023 from the sale of Micropump as compared with $49.4 million in 2022 from the sale of Knight. These decreases in cash flows used in investing activities were partially offset by higher capital expenditures of $68.3 million in 2023 as compared with $48.0 million in 2022 and the purchase of marketable securities in 2023 for $24.6 million.

Financing Activities

Cash flows used in financing activities during the nine months ended September 30, 2023 primarily consisted of payments of $150.0 million on the Term Facility and dividends of $142.3 million paid to common shareholders. Cash flows used in financing activities during the nine months ended September 30, 2022 primarily consisted of the repurchase of 788,623 shares for $146.3 million and dividends of $132.2 million paid to common shareholders.

Free Cash Flow

The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures.

The following table reconciles free cash flow to cash flows provided by operating activities:

Nine Months Ended September 30,
(Dollars in millions)20232022
Cash flows provided by operating activities$515.7 $390.1 
Less: capital expenditures 68.3 48.0 
Free cash flow$447.4 $342.1 
Free cash flow as a percent of adjusted net income attributable to IDEX92.3 %73.5 %

The increase in free cash flow as compared to 2022 is due to lower investments in working capital in 2023 as discussed above as compared with 2022, partially offset by higher capital expenditures.

39


Cash Requirements

Capital Expenditures

Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $68.3 million and $48.0 million in the first nine months of 2023 and 2022, respectively.

Share Repurchases

During the nine months ended September 30, 2023, the Company repurchased 5,400 shares at a cost of $1.1 million. As of September 30, 2023, the amount of share repurchase authorization remaining was $562.8 million. For additional information regarding the Company’s share repurchase program, refer to Note 14 in the Notes to Condensed Consolidated Financial Statements.

Dividends

Total dividend payments to common shareholders were $142.3 million during the nine months ended September 30, 2023 compared with $132.2 million during the nine months ended September 30, 2022.

Covenants

The key financial covenants that the Company is required to maintain in connection with the Revolving Credit Facility, the Term Facility, the 3.37% Senior Notes and the 5.13% Senior Notes, are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1. At September 30, 2023, the Company was in compliance with these financial covenants, as the Company’s interest coverage ratio was 18.62 to 1 for covenant calculation purposes and the leverage ratio was 1.42 to 1. There are no financial covenants relating to the 2.625% Senior Notes or the 3.00% Senior Notes; however, both are subject to cross-default provisions.

Credit Ratings

The Company’s credit ratings, which were independently developed by the following credit agencies, are detailed below:

•S&P Global Ratings reaffirmed the Company’s corporate credit rating of BBB (stable outlook) in August 2023.

•Moody’s Investors Service affirmed the Company’s corporate credit rating of Baa2 (stable outlook) in December 2021.

•Fitch Ratings reaffirmed the Company’s corporate credit rating of BBB+ (stable outlook) in April 2023.

Critical Accounting Estimates

As discussed in the Annual Report on Form 10-K for the year ended December 31, 2022, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. There have been no changes to the Company’s critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2022.

40

Non-GAAP Disclosures

Set forth below are reconciliations of Organic net sales, Adjusted net sales, Adjusted gross profit, Adjusted gross margin, Adjusted net income attributable to IDEX, Adjusted diluted earnings per share (“EPS”) attributable to IDEX, Consolidated Adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Consolidated Adjusted EBITDA margin to their respective most directly comparable U.S. GAAP measure. Management uses these metrics to measure performance of the Company since they exclude items that are not reflective of ongoing operations, as identified in the reconciliations below. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.

This report references organic sales, a non-GAAP measure, that excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture and (3) the impact from the exit of a COVID-19 testing application. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping to identify underlying growth trends in the Company’s business and facilitating easier comparisons of the Company’s revenue with prior and future periods and to its peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long-term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers. The Company excludes the impact from the exit of a COVID-19 testing application because it is not reflective of ongoing operations and can obscure underlying business trends.

Management believes that Adjusted EBITDA, which is EBITDA adjusted for items that are not reflective of ongoing operations, is useful as a performance indicator of ongoing operations. The Company believes that Adjusted EBITDA is useful to investors as an indicator of the strength and performance of the Company and its segments’ ongoing business operations as well as a way to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.

This report also references free cash flow. This non-GAAP measure is discussed and reconciled to its most directly comparable U.S. GAAP measure in the section titled “Free Cash Flow.”

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

1. Reconciliations of the Change in Net Sales to Organic Net Sales
Three Months Ended September 30, 2023
FMTHSTFSDPIDEX
Change in net sales(2 %)(9 %)5 %(4 %)
Net impact from acquisitions/divestitures2 %(10 %)— %(3 %)
Impact from foreign currency(1 %)(1 %)(2 %)(1 %)
Impact from the exit of a COVID-19 testing application(1)
— %5 %— %2 %
Change in organic net sales(1 %)(15 %)3 %(6 %)


41

Nine Months Ended September 30, 2023
FMTHSTFSDPIDEX
Change in net sales8 %2 %6 %5 %
Net impact from acquisitions/divestitures(2 %)(10 %)— %(5 %)
Impact from foreign currency— %— %1 %— %
Impact from the exit of a COVID-19 testing application(1)
— %2 %— %1 %
Change in organic net sales6 %(6 %)7 %1 %

(1) Represents the acceleration of previously deferred revenue of $17.9 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

2. Reconciliations of Reported-to-Adjusted Gross Profit, Net Sales and Gross Margin (dollars in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Gross profit$349.6$381.8$1,110.1$1,081.2
Impact from the exit of a COVID-19 testing application(1)
—(17.9)—(17.9)
Fair value inventory step-up charges1.2—1.20.4
Adjusted gross profit$350.8$363.9$1,111.3$1,063.7
Net sales$793.4$824.0$2,485.0$2,371.2
Impact from the exit of a COVID-19 testing application(1)
—(17.9)—(17.9)
Adjusted net sales$793.4$806.1$2,485.0$2,353.3
Gross margin44.1 %46.3 %44.7 %45.6 %
Adjusted gross margin44.2 %45.1 %44.7 %45.2 %

(1) Represents the acceleration of previously deferred revenue of $17.9 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

42

3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Reported net income attributable to IDEX$209.1 $178.7 $487.5 $456.9 
Fair value inventory step-up charges1.2 — 1.2 0.4 
Tax impact on fair value inventory step-up charges(0.3)— (0.3)(0.1)
Restructuring expenses and asset impairments4.1 — 8.2 2.8 
Tax impact on restructuring expenses and asset impairments(0.9)— (1.8)(0.7)
Net impact from the exit of a COVID-19 testing application(1)
— (1.1)— (1.1)
Tax impact on the exit of a COVID-19 testing application— 0.3 — 0.3 
Gain on sale of business(93.8)(34.8)(93.8)(34.8)
Tax impact on gain on sale of business22.7 5.5 22.7 5.5 
Gains on sales of assets— — — (2.7)
Tax impact on gains on sales of assets— — — 0.6 
Credit loss on note receivable from collaborative partner(2)
— — 7.7 — 
Tax impact on credit loss on note receivable from collaborative partner— — (1.6)— 
Acquisition-related intangible asset amortization23.8 17.0 70.6 49.2 
Tax impact on acquisition-related intangible asset amortization(5.3)(3.7)(15.8)(11.0)
Adjusted net income attributable to IDEX$160.6 $161.9 $484.6 $465.3 

(1) Represents the net impact of the acceleration of previously deferred revenue of $17.9 million and an impairment charge of $16.8 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

(2) Represents a reserve recorded on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.

43

3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (continued)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Reported diluted EPS attributable to IDEX$2.75 $2.36 $6.42 $6.00 
Fair value inventory step-up charges0.02 — 0.02 — 
Tax impact on fair value inventory step-up charges— — — — 
Restructuring expenses and asset impairments0.06 — 0.11 0.04 
Tax impact on restructuring expenses and asset impairments(0.01)— (0.03)(0.01)
Net impact from the exit of a COVID-19 testing application(1)
— (0.01)— (0.01)
Tax impact on the exit of a COVID-19 testing application— — — — 
Gain on sale of business(1.24)(0.46)(1.24)(0.46)
Tax impact on gain on sale of business0.30 0.07 0.30 0.07 
Gains on sales of assets— — — (0.03)
Tax impact on gains on sales of assets— — — 0.01 
Credit loss on note receivable from collaborative partner(2)
— — 0.10 — 
Tax impact on credit loss on note receivable from collaborative partner— — (0.02)— 
Acquisition-related intangible asset amortization0.31 0.23 0.93 0.65 
Tax impact on acquisition-related intangible asset amortization(0.07)(0.05)(0.21)(0.14)
Adjusted diluted EPS attributable to IDEX$2.12 $2.14 $6.38 $6.12 
Diluted weighted average shares outstanding75.9 75.8 75.9 76.1 

(1) Represents the net impact of the acceleration of previously deferred revenue of $17.9 million and an impairment charge of $16.8 million as a result of a customer’s decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

(2) Represents a reserve recorded on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.

44

4. Reconciliations of Net Income to Adjusted EBITDA and Net Sales to Adjusted Net Sales (dollars in millions)
Three Months Ended September 30,
20232022
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported net income$—$—$—$—$209.0$—$—$—$—$178.7
Provision for income taxes————52.8————49.7
Interest expense————13.7————9.6
Other (income) expense - net————(2.1)————(1.0)
(Gain) on sale of business————(93.8)————(34.8)
Operating income (loss)92.154.748.4(15.6)179.694.585.643.6(21.5)202.2
Other income (expense) - net1.11.30.2(0.5)2.10.21.10.5(0.8)1.0
Depreciation3.19.02.30.314.73.96.22.10.112.3
Amortization5.616.71.5—23.85.89.61.6—17.0
 Fair value inventory step-up charges—1.2——1.2—————
Restructuring expenses and asset impairments1.71.50.40.54.1—————
Net impact from the exit of a COVID-19 testing application(1)
——————(1.1)——(1.1)
Adjusted EBITDA$103.6$84.4$52.8$(15.3)$225.5$104.4$101.4$47.8$(22.2)$231.4
Net sales (eliminations)$301.1$313.2$180.6$(1.5)$793.4$307.6$345.0$172.4$(1.0)$824.0
Impact from the exit of a COVID-19 testing application(1)
— — — — — — (17.9)— — (17.9)
Adjusted net sales (eliminations)$301.1$313.2$180.6$(1.5)$793.4$307.6$327.1$172.4$(1.0)$806.1
Net income margin26.3 %21.7 %
Adjusted EBITDA margin34.4 %26.9 %29.3 %n/m28.4 %33.9 %31.0 %27.8 %n/m28.7 %

(1) The net impact in the Adjusted EBITDA reconciliation represents the acceleration of previously deferred revenue of $17.9 million less the impairment charge of $16.8 million related to a customer's decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023, while the impact in the Adjusted net sales reconciliation represents only the acceleration of previously deferred revenue of $17.9 million discussed above. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.





45

4. Reconciliations of Net Income to Adjusted EBITDA and Net Sales to Adjusted Net Sales (dollars in millions) (continued)
Nine Months Ended September 30,
20232022
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported net income$—$—$—$—$487.3$—$—$—$—$456.7
Provision for income taxes————132.8————129.2
Interest expense————40.1————28.6
Other (income) expense - net————5.6————(3.3)
(Gain) on sale of business————(93.8)————(34.8)
Operating income (loss)291.9199.7145.0(64.6)572.0257.8255.7124.0(61.1)576.4
Other income (expense) - net2.00.8(0.3)(8.1)(5.6)2.02.52.6(3.8)3.3
Depreciation10.324.16.70.841.912.018.46.30.337.0
Amortization17.348.54.8—70.615.129.24.9—49.2
Fair value inventory step-up charges—1.2——1.20.4———0.4
Restructuring expenses and asset impairments2.44.50.80.58.21.70.11.0—2.8
Net impact from the exit of a COVID-19 testing application(1)
——————(1.1)——(1.1)
Gains on sales of assets—————(1.2)—(1.5)—(2.7)
Credit loss on note receivable from collaborative partner(2)
———7.77.7—————
Adjusted EBITDA$323.9$278.8$157.0$(63.7)$696.0$287.8$304.8$137.3$(64.6)$665.3
Net sales (eliminations)$948.0$1,003.7$539.8$(6.5)$2,485.0$879.5$986.2$508.3$(2.8)$2,371.2
Impact from the exit of a COVID-19 testing application(1)
— — — — — — (17.9)— — (17.9)
Adjusted net sales (eliminations)$948.0$1,003.7$539.8$(6.5)$2,485.0$879.5$968.3$508.3$(2.8)$2,353.3
Net income margin19.6 %19.3 %
Adjusted EBITDA margin34.2 %27.8 %29.1 %n/m28.0 %32.7 %31.5 %27.0 %n/m28.3 %

(1) The net impact in the Adjusted EBITDA reconciliation represents the acceleration of previously deferred revenue of $17.9 million less the impairment charge of $16.8 million related to a customer's decision to discontinue further investment in commercializing its COVID-19 testing application in 2022 that did not reoccur in 2023, while the impact in the Adjusted net sales reconciliation represents only the acceleration of previously deferred revenue of $17.9 million discussed above. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.

(2) Represents a reserve recorded on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.















46

Cautionary Statement Under the Private Securities Litigation Reform Act

This quarterly report on Form 10-Q, including the “Overview,” “Results of Operations” and “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, anticipated changes in the fourth quarter of 2023, anticipated future acquisition behavior, expectations regarding customer destocking efforts and future order stabilization and lead time, availability of cash and financing alternatives and the anticipated benefits of the Company’s recent acquisitions, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets and adverse developments affecting the financial services industry; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results; the impact of health epidemics and pandemics and terrorist attacks and wars, which could have an adverse impact on the Company's business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.





















47

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes with respect to market risks disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4.    Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2023.

There has been no change in the Company’s internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

48

PART II. OTHER INFORMATION
 
Item 1.    Legal Proceedings

The Company and its subsidiaries are party to legal proceedings arising in the ordinary course of business as described in Note 17 in Part I, Item 1, “Commitments and Contingencies,” and such disclosure is incorporated by reference into this Item 1. “Legal Proceedings.”

The Company’s threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.

In addition, the Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Asbestos-related claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.

Item 1A. Risk Factors

There have been no material changes with respect to risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about the Company’s purchases of its common stock during the quarter ended September 30, 2023:
PeriodTotal Number of
Shares Purchased		Average Price
Paid per Share		Total Number of
Shares Purchased as
Part of Publicly
Announced Plans
or Programs
Approximate Dollar
Value that May Yet
be Purchased
Under the Plans
or Programs(1)
July 1, 2023 to July 31, 2023— $— — $562,763,657 
August 1, 2023 to August 31, 2023— — — 562,763,657 
September 1, 2023 to September 30, 2023— — — 562,763,657 
Total— $— — $562,763,657 

(1)On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorization of the Board of Directors of $300.0 million on December 1, 2015. These authorizations have no expiration date.

Item 5.    Other Information

During the quarter ended September 30, 2023, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
49
Table of Contents

Item 6.    Exhibits

Exhibit
Number		Description
10.1*,**
Termination and Release Agreement between Fast & Fluid Management B.V. and M.A. Uleman, dated as of August 31, 2023
31.1*
Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002
31.2*
Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002
32.1*
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2*
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350
101*The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 formatted in Inline eXtensible Business Reporting Language (iXBRL) includes: (i) the Cover Page, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Income, (iv) the Condensed Consolidated Statements of Comprehensive Income, (v) the Condensed Consolidated Statements of Equity, (vi) the Condensed Consolidated Statements of Cash Flows, and (vii) Notes to Condensed Consolidated Financial Statements.
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Management contract or compensatory plan or agreement.

50

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
IDEX Corporation
By:/s/ ALLISON S. LAUSAS
Allison S. Lausas
Interim Chief Financial Officer and Chief Accounting Officer
(Principal Financial and Accounting Officer)
Date: October 26, 2023
51

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

© 2025 CompaniesMarketcap.com